WO2009027732A1 - 5-6-bicyclic heteroaromatic compounds with antibacterial activity - Google Patents
5-6-bicyclic heteroaromatic compounds with antibacterial activity Download PDFInfo
- Publication number
- WO2009027732A1 WO2009027732A1 PCT/GB2008/050734 GB2008050734W WO2009027732A1 WO 2009027732 A1 WO2009027732 A1 WO 2009027732A1 GB 2008050734 W GB2008050734 W GB 2008050734W WO 2009027732 A1 WO2009027732 A1 WO 2009027732A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infection
- methyl
- compound
- carbamoyl
- compound according
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 219
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 143
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 143
- 238000000034 method Methods 0.000 claims abstract description 71
- 150000003839 salts Chemical class 0.000 claims abstract description 68
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 208000015181 infectious disease Diseases 0.000 claims description 244
- -1 cyano, hydroxy Chemical group 0.000 claims description 164
- 241001465754 Metazoa Species 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 108010041052 DNA Topoisomerase IV Proteins 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 27
- 230000005764 inhibitory process Effects 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 20
- 206010040047 Sepsis Diseases 0.000 claims description 16
- 206010006451 bronchitis Diseases 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 14
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 14
- 229960003085 meticillin Drugs 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 208000019206 urinary tract infection Diseases 0.000 claims description 13
- 108020000946 Bacterial DNA Proteins 0.000 claims description 12
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 206010001076 Acute sinusitis Diseases 0.000 claims description 11
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 11
- 206010031252 Osteomyelitis Diseases 0.000 claims description 11
- 206010014665 endocarditis Diseases 0.000 claims description 11
- 208000022760 infectious otitis media Diseases 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 8
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical group 0.000 claims 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 29
- 238000002360 preparation method Methods 0.000 abstract description 9
- 239000000543 intermediate Substances 0.000 description 78
- 239000007787 solid Substances 0.000 description 67
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- 239000000203 mixture Substances 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 52
- 239000000243 solution Substances 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
- 239000011541 reaction mixture Substances 0.000 description 49
- 229910001868 water Inorganic materials 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000007858 starting material Substances 0.000 description 29
- 108010054814 DNA Gyrase Proteins 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 238000001914 filtration Methods 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 229960004132 diethyl ether Drugs 0.000 description 15
- 229940093499 ethyl acetate Drugs 0.000 description 15
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 206010057190 Respiratory tract infections Diseases 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 206010035664 Pneumonia Diseases 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000005843 halogen group Chemical group 0.000 description 9
- 230000000155 isotopic effect Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 241000606161 Chlamydia Species 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000007859 condensation product Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 7
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 150000007660 quinolones Chemical class 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000005864 Sulphur Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010008326 Cervicitis gonococcal Diseases 0.000 description 5
- 206010061977 Genital infection female Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000019802 Sexually transmitted disease Diseases 0.000 description 5
- 101710183280 Topoisomerase Proteins 0.000 description 5
- ZGSDJMADBJCNPN-UHFFFAOYSA-N [S-][NH3+] Chemical compound [S-][NH3+] ZGSDJMADBJCNPN-UHFFFAOYSA-N 0.000 description 5
- 201000010439 acute gonococcal cervicitis Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 201000004308 chancroid Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 208000028320 gonococcal cervicitis Diseases 0.000 description 5
- 208000020426 gonococcal urethritis Diseases 0.000 description 5
- 244000000059 gram-positive pathogen Species 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 208000006379 syphilis Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 3
- MKGJGBMWZJCRDE-UHFFFAOYSA-N 1-(8-carbamothioyl-9-methyl-6-morpholin-4-ylpurin-2-yl)-3-ethylurea Chemical compound C=12N=C(C(N)=S)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCOCC1 MKGJGBMWZJCRDE-UHFFFAOYSA-N 0.000 description 3
- ARQOTZADDARBTR-UHFFFAOYSA-N 1-(8-carbamothioyl-9-methyl-6-piperidin-1-ylpurin-2-yl)-3-ethylurea Chemical compound C=12N=C(C(N)=S)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCCCC1 ARQOTZADDARBTR-UHFFFAOYSA-N 0.000 description 3
- QSCSEFALFSNDBO-UHFFFAOYSA-N 1-[8-carbamothioyl-6-(2-fluorophenyl)-9-methylpurin-2-yl]-3-ethylurea Chemical compound C=12N=C(C(N)=S)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC=C1F QSCSEFALFSNDBO-UHFFFAOYSA-N 0.000 description 3
- VYRFRTQJLYPYDS-UHFFFAOYSA-N 1-[8-carbamothioyl-9-methyl-6-(3-methylphenyl)purin-2-yl]-3-ethylurea Chemical compound C=12N=C(C(N)=S)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC(C)=C1 VYRFRTQJLYPYDS-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004150 EU approved colour Substances 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000007080 aromatic substitution reaction Methods 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 150000001721 carbon Chemical class 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- DZVLPPIYTVOABE-UHFFFAOYSA-N ethyl 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperazin-1-ylpurin-8-yl]-1,3-thiazole-4-carboxylate Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)OCC)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCNCC1 DZVLPPIYTVOABE-UHFFFAOYSA-N 0.000 description 3
- UMIIHJRCVZLERX-UHFFFAOYSA-N ethyl 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperidin-1-ylpurin-8-yl]-1,3-thiazole-4-carboxylate Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)OCC)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCCCC1 UMIIHJRCVZLERX-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 244000000058 gram-negative pathogen Species 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 3
- 229940107698 malachite green Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- OUXOVFIVVDDNAO-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-6-(2-fluorophenyl)-9-methylpurin-8-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C=12N=C(C=3SC=C(N=3)C(O)=O)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC=C1F OUXOVFIVVDDNAO-UHFFFAOYSA-N 0.000 description 2
- RRFJVRVOFHSHKK-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-morpholin-4-ylpurin-8-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C=12N=C(C=3SC=C(N=3)C(O)=O)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCOCC1 RRFJVRVOFHSHKK-UHFFFAOYSA-N 0.000 description 2
- HKEKZDSRDNTSAK-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperidin-1-ylpurin-8-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C=12N=C(C=3SC=C(N=3)C(O)=O)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCCCC1 HKEKZDSRDNTSAK-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- ABIFCPFZAUZUJU-UHFFFAOYSA-N 2-amino-6-chloro-9-methylpurine-8-carbonitrile Chemical compound N1=C(N)N=C2N(C)C(C#N)=NC2=C1Cl ABIFCPFZAUZUJU-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QEIRYIILFUVXAM-UHFFFAOYSA-N 6-chloropyridine-2,3-diamine Chemical compound NC1=CC=C(Cl)N=C1N QEIRYIILFUVXAM-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 230000007035 DNA breakage Effects 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- ISKQADXMHQSTHK-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=C(CN)C=C1 ISKQADXMHQSTHK-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 208000024833 burkholderia infectious disease Diseases 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- BHXMPJYEOFJMJD-UHFFFAOYSA-N ethyl 2-(2-amino-6-chloro-5-formylpyrimidin-4-yl)sulfanylacetate Chemical compound CCOC(=O)CSC1=NC(N)=NC(Cl)=C1C=O BHXMPJYEOFJMJD-UHFFFAOYSA-N 0.000 description 2
- RMWBORBPUFYQIV-UHFFFAOYSA-N ethyl 2-[2-(ethylcarbamoylamino)-9-methyl-6-(3-methylphenyl)purin-8-yl]-1,3-thiazole-4-carboxylate Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)OCC)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC(C)=C1 RMWBORBPUFYQIV-UHFFFAOYSA-N 0.000 description 2
- QQMHKYSBOBMQCM-UHFFFAOYSA-N ethyl 2-[2-(ethylcarbamoylamino)-9-methyl-6-morpholin-4-ylpurin-8-yl]-1,3-thiazole-4-carboxylate Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)OCC)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCOCC1 QQMHKYSBOBMQCM-UHFFFAOYSA-N 0.000 description 2
- JRYVSGPZXKXELQ-UHFFFAOYSA-N ethyl 2-amino-4-pyridin-4-ylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C(N)N=C2SC(C(=O)OCC)=CC2=C1C1=CC=NC=C1 JRYVSGPZXKXELQ-UHFFFAOYSA-N 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 229960002950 novobiocin Drugs 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- URFRLQSPHIMOBZ-UHFFFAOYSA-N tert-butyl 4-[8-carbamothioyl-2-(ethylcarbamoylamino)-9-methylpurin-6-yl]piperazine-1-carboxylate Chemical compound C=12N=C(C(N)=S)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCN(C(=O)OC(C)(C)C)CC1 URFRLQSPHIMOBZ-UHFFFAOYSA-N 0.000 description 2
- OTQZQKHPCQADGO-UHFFFAOYSA-N tert-butyl 4-[8-cyano-2-(ethylcarbamoylamino)-9-methylpurin-6-yl]piperazine-1-carboxylate Chemical compound C=12N=C(C#N)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCN(C(=O)OC(C)(C)C)CC1 OTQZQKHPCQADGO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HMHQWJDFNVJCHA-BTZKOOKSSA-N (2s)-2-[[(5r,8s)-8-[[(2s,3r)-1-[(2s)-2-amino-3-hydroxypropanoyl]-3-hydroxypyrrolidine-2-carbonyl]amino]-14,16-dihydroxy-13-methyl-7,11-dioxo-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-triene-5-carbonyl]amino]propanoic acid Chemical compound N([C@H]1COC(=O)C2=C(C)C(O)=CC(O)=C2CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)C(=O)[C@@H]1[C@H](O)CCN1C(=O)[C@@H](N)CO HMHQWJDFNVJCHA-BTZKOOKSSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 1
- HXILLXLREZMRMW-UHFFFAOYSA-N 2-(ethylcarbamoylamino)-4-pyridin-4-ylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound C=12C=C(C(N)=O)SC2=NC(NC(=O)NCC)=NC=1C1=CC=NC=C1 HXILLXLREZMRMW-UHFFFAOYSA-N 0.000 description 1
- AUFJTVGCSJNQIF-UHFFFAOYSA-N 2-Amino-4,6-dihydroxypyrimidine Chemical compound NC1=NC(O)=CC(=O)N1 AUFJTVGCSJNQIF-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- SVUVIWAFGSVVHP-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-6-(2-fluorophenyl)-9-methylpurin-8-yl]-n-methyl-1,3-thiazole-4-carboxamide Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)NC)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC=C1F SVUVIWAFGSVVHP-UHFFFAOYSA-N 0.000 description 1
- WWJOLJBSOCTKAG-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-(3-methylphenyl)purin-8-yl]-n-methyl-1,3-thiazole-4-carboxamide Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)NC)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC(C)=C1 WWJOLJBSOCTKAG-UHFFFAOYSA-N 0.000 description 1
- JHHDMAZLNWNKGS-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-morpholin-4-ylpurin-8-yl]-n-methyl-1,3-thiazole-4-carboxamide Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)NC)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCOCC1 JHHDMAZLNWNKGS-UHFFFAOYSA-N 0.000 description 1
- GCPYGRGJJKBUQJ-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperazin-1-ylpurin-8-yl]-1,3-thiazole-4-carboxamide Chemical compound C=12N=C(C=3SC=C(N=3)C(N)=O)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCNCC1 GCPYGRGJJKBUQJ-UHFFFAOYSA-N 0.000 description 1
- YCKCPTJCCAPECK-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperazin-1-ylpurin-8-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C=12N=C(C=3SC=C(N=3)C(O)=O)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCNCC1 YCKCPTJCCAPECK-UHFFFAOYSA-N 0.000 description 1
- XJWCNEXXDKWIQU-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperidin-1-ylpurin-8-yl]-1,3-thiazole-4-carboxamide Chemical compound C=12N=C(C=3SC=C(N=3)C(N)=O)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCCCC1 XJWCNEXXDKWIQU-UHFFFAOYSA-N 0.000 description 1
- QJCKPDMKMPBEIF-UHFFFAOYSA-N 2-[2-(ethylcarbamoylamino)-9-methyl-6-piperidin-1-ylpurin-8-yl]-n-methyl-1,3-thiazole-4-carboxamide Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)NC)N(C)C2=NC(NC(=O)NCC)=NC=1N1CCCCC1 QJCKPDMKMPBEIF-UHFFFAOYSA-N 0.000 description 1
- VKCMHMGCOCGDDH-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-yl)-2-(ethylcarbamoylamino)thieno[2,3-d]pyrimidin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound S1C2=NC(NC(=O)NCC)=NC(C=3SC4=CC=CC=C4N=3)=C2C=C1C1=NC(C(O)=O)=CS1 VKCMHMGCOCGDDH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- UUIMDJFBHNDZOW-UHFFFAOYSA-N 2-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=CC=N1 UUIMDJFBHNDZOW-UHFFFAOYSA-N 0.000 description 1
- YJQBZFOBZMDVHX-UHFFFAOYSA-N 3-amino-1h-pyridin-2-one;hydrochloride Chemical compound Cl.NC1=CC=CNC1=O YJQBZFOBZMDVHX-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-M 3-bromopyruvate Chemical compound [O-]C(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- WIFDRGRXGYPBCY-UHFFFAOYSA-N 5-chloro-2-pyridin-3-yl-[1,3]oxazolo[5,4-b]pyridine Chemical compound O1C2=NC(Cl)=CC=C2N=C1C1=CC=CN=C1 WIFDRGRXGYPBCY-UHFFFAOYSA-N 0.000 description 1
- SCGNWULOSYKTQP-UHFFFAOYSA-N 6-chloro-3-nitro-1h-pyridin-2-one Chemical compound [O-][N+](=O)C1=CC=C(Cl)NC1=O SCGNWULOSYKTQP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241001148231 Acinetobacter haemolyticus Species 0.000 description 1
- 241000122229 Acinetobacter johnsonii Species 0.000 description 1
- 241000122230 Acinetobacter junii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241001464890 Anaerococcus prevotii Species 0.000 description 1
- 241001464898 Anaerococcus tetradius Species 0.000 description 1
- 241001464864 Anaerococcus vaginalis Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001464887 Parvimonas micra Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108091068141 Type II family Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 description 1
- FJAQNRBDVKIIKK-LFLQOBSNSA-N [(3r,4s,5r,6s)-6-[8-chloro-4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-2-oxochromen-7-yl]oxy-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1h-pyrrole-2-carboxylate Chemical compound O([C@@H]1[C@H](C(O[C@@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C=C(CC=C(C)C)C(O)=CC=4)=C(O)C3=CC=2)Cl)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 FJAQNRBDVKIIKK-LFLQOBSNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- FJAQNRBDVKIIKK-UHFFFAOYSA-N chlorobiocin Natural products OC1C(OC=2C(=C3OC(=O)C(NC(=O)C=4C=C(CC=C(C)C)C(O)=CC=4)=C(O)C3=CC=2)Cl)OC(C)(C)C(OC)C1OC(=O)C1=CC=C(C)N1 FJAQNRBDVKIIKK-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HMHQWJDFNVJCHA-UHFFFAOYSA-N cyclothialidine Natural products O=C1NC(C(=O)NC(C)C(O)=O)CSCC2=C(O)C=C(O)C(C)=C2C(=O)OCC1NC(=O)C1C(O)CCN1C(=O)C(N)CO HMHQWJDFNVJCHA-UHFFFAOYSA-N 0.000 description 1
- 108010083968 cyclothialidine Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- LWJYMKDMGMOTSB-UHFFFAOYSA-L dichlorotin;hydrate Chemical compound O.Cl[Sn]Cl LWJYMKDMGMOTSB-UHFFFAOYSA-L 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- LYTDSTYKQVWEME-UHFFFAOYSA-N ethyl 2-(ethylcarbamoylamino)-4-pyridin-4-ylthieno[2,3-d]pyrimidine-6-carboxylate Chemical compound C=12C=C(C(=O)OCC)SC2=NC(NC(=O)NCC)=NC=1C1=CC=NC=C1 LYTDSTYKQVWEME-UHFFFAOYSA-N 0.000 description 1
- KWACLJZHNZZVPR-UHFFFAOYSA-N ethyl 2-[2-(ethylcarbamoylamino)-4-pyridin-4-ylthieno[2,3-d]pyrimidin-6-yl]-1,3-thiazole-4-carboxylate Chemical compound C=12C=C(C=3SC=C(N=3)C(=O)OCC)SC2=NC(NC(=O)NCC)=NC=1C1=CC=NC=C1 KWACLJZHNZZVPR-UHFFFAOYSA-N 0.000 description 1
- OCMAKZNYFULLHX-UHFFFAOYSA-N ethyl 2-[2-(ethylcarbamoylamino)-6-(2-fluorophenyl)-9-methylpurin-8-yl]-1,3-thiazole-4-carboxylate Chemical compound C=12N=C(C=3SC=C(N=3)C(=O)OCC)N(C)C2=NC(NC(=O)NCC)=NC=1C1=CC=CC=C1F OCMAKZNYFULLHX-UHFFFAOYSA-N 0.000 description 1
- IESIMTFCAGZJSR-UHFFFAOYSA-N ethyl 2-amino-4-(4-formylphenyl)thieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C(N)N=C2SC(C(=O)OCC)=CC2=C1C1=CC=C(C=O)C=C1 IESIMTFCAGZJSR-UHFFFAOYSA-N 0.000 description 1
- RVSQDXBPGDMBIQ-UHFFFAOYSA-N ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate Chemical compound N1=C(N)N=C2SC(C(=O)OCC)=CC2=C1Cl RVSQDXBPGDMBIQ-UHFFFAOYSA-N 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 101150013736 gyrB gene Proteins 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SNDOVHBMTXRXOT-UHFFFAOYSA-N n-(6-chloro-2-oxo-1h-pyridin-3-yl)pyridine-3-carboxamide Chemical compound O=C1NC(Cl)=CC=C1NC(=O)C1=CC=CN=C1 SNDOVHBMTXRXOT-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 101150012629 parE gene Proteins 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- WQYZWQAFPNONEM-UHFFFAOYSA-N tert-butyl 5-(ethylcarbamoylamino)-2-pyridin-3-ylimidazo[4,5-b]pyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)N1C2=NC(NC(=O)NCC)=CC=C2N=C1C1=CC=CN=C1 WQYZWQAFPNONEM-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
- this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
- bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens.
- Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity.
- Gram-positive pathogens for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established.
- strains examples include methicillin resistant staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiple resistant Enter ococcus faecium.
- MRSA methicillin resistant staphylococcus aureus
- MRCNS methicillin resistant coagulase negative staphylococci
- Streptococcus pneumoniae and multiple resistant Enter ococcus faecium.
- Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as ⁇ -lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H. influenzae and M. catarrhalis.
- DNA gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA.
- ATP adenosine triphosphate
- DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA.
- the enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A 2 B 2 tetrameric complex.
- the A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage.
- the B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.
- topoisomerase IV Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109).
- DNA gyrase is a well-validated target of antibacterials, including the quinolones and the coumarins.
- the quinolones ⁇ e.g. ciprofloxacin
- the quinolones are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol.
- cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).
- Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomerase IV are known in the art.
- coumarin-containing compounds are described in patent application number WO 99/35155
- 5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879
- pyrazole compounds are described in patent application WO 01/52845 (US patent US6,608,087).
- AstraZeneca has also published certain applications describing anti-bacterial compounds: WO2005/026149, WO2006/087544, WO2006/087548, WO2006/087543, WO2006/092599, WO2006/092608, WO2007/071965, WO2008/020227, WO2008/020222, WO2008/020229, and WO2008/068470.
- the compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.
- R 1 is selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 3-6 cycloalkyl; wherein R 1 may be optionally substituted on carbon by one or more R 5 ;
- R 2 is selected from hydrogen or Ci_6alkyl; wherein said may be optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, nitro and amino;
- Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 11 ;
- R 3 , R 6 , R 7 , R 9 and R 10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkanoyl, Ci_6alkanoyloxy, 7V-(Ci-6alkyl)amino, ⁇ /,N-(Ci-6alkyl)2amino, Ci.6alkanoylamino, ⁇ /-(Ci-6alkyl)carbamoyl, ⁇ /, ⁇ /-(Ci -6 alkyl) 2 carbamoyl, ⁇ /-(Ci.
- R 4 is a substituent on carbon is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C ⁇ alkyl, C2-6alkenyl, C 2 - 6 alkynyl, Ci_6alkoxy, ⁇ /-(Ci.
- Ci.6alkylS(O) a wherein a is 0 to 2, Ci_6alkoxycarbonyl, Ci- ⁇ alkoxycarbonylamino, ⁇ /-(Ci- 6 alkyl)sulphamoyl, ⁇ /,N-(Ci -6 alkyl)2Sulphamoyl, d- ⁇ alkylsulphonylamino, carbocyclyl-R 16 - or heterocyclyl-R 17 -; wherein R 4 may be optionally substituted on carbon by one or more R 18 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 19 ;
- R 5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci- ⁇ alkyl, C 2 - 6 alkenyl, C2-6alkynyl, Ci_6alkanoyl, Ci_6alkanoyloxy, ⁇ /-(Ci- 6 alkyl)amino, Ci. 6 alkanoylamino and C 3 _ 6 cycloalkyl;
- R 8 is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, Ci -6 alkanoyl, Ci_6alkylsulphonyl, Ci_6alkoxycarbonyl, carbamoyl, TV-(C i-6alkyl)carbamoyl, ⁇ /, ⁇ /-(Ci. 6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
- R 12 , R 13 , R 16 and R 17 are independent selected from a direct bond, -O-, -N(R 20 )-, -C(O)-, -N(R 21 )C(O)-, -C(O)N(R 22 )-, -S(O) 8 -, -SO 2 N(R 23 )- or -N(R 24 )SO 2 -; wherein R 20 , R 21 , R 22 , R 23 and R 24 are independently selected from hydrogen or and s is 0-2; and
- R ⁇ , R 15 and R 19 are independently selected from Ci_6alkyl, C 3 _ 6 cycloalkyl, Ci-6alkanoyl, Ci- ⁇ alkylsulphonyl, Ci- ⁇ alkoxycarbonyl, carbamoyl, ⁇ /-(Ci- 6 alkyl)carbamoyl, ⁇ /, ⁇ /-(Ci.
- R 14 and R 18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylamino, acetylamino, ⁇ /-methylcarbamoyl, iV-ethylcarbamoyl, ⁇ /, ⁇ /-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, 7V-methyl-7V-ethylcarbamo
- R 1 , R 2 , R 4 , X 1 , X 2 , X 3 , ring A and n are as defined in formula (I);
- R 3 is selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C ⁇ aUcyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, Ci_6alkanoyl, Ci_6alkanoyloxy, ⁇ /-(Ci-6alkyl)amino, ⁇ /, ⁇ /-(Ci-6alkyl)2amino, ⁇ /, ⁇ /-(Ci.
- R 14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifiuoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dime thy lamino, diethylamino, 7V-methyl-7V-ethylamino, acetylamino, 7V-methylcarbamoyl, JV-ethylcarbamoyl, ⁇ iV-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, TV-methyl-TV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethy
- X 2 and X 3 are not both selected from (i) because the bond between -C(X 2 )- and -C(Ring A)- and the bond between -C(Ring A)- and -C(X 3 )- in formula (I) or (V) cannot both be double bonds.
- the compounds represented by formula (I) or (I') do not include the compounds in Table A.
- the invention provides pharmaceutical compositions comprising a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
- the invention provides a method of inhibiting bacterial DNA gyrase and/or bacterial topoisomerase IV in a warm-blooded animal in need of such treatment, comprising administering to the animal an effective amount of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof.
- the warm-blooded animal is a human.
- the invention provides a method of producing an antibacterial effect in a warm-blooded animal in need of such treatment, comprising administering to the animal an effective amount of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof.
- the warm-blooded animal is a human.
- the invention provides a method of treating a bacterial infection in a warm-blooded animal in need thereof, comprising administering to the animal an effective amount of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof.
- the warm-blooded animal is a human.
- the bacterial infection is selected from the group consisting of community- acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections and infections caused by drug resistant bacteria such as Penicillin-resistant Streptococcus pneumoniae, methicillin- resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and
- the warm-blooded animal is a human.
- the invention provides the use of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the production of an antibacterial effect in a warm-blooded animal.
- the warm-blooded animal is a human.
- the invention provides the use of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomerase IV in a warm- blooded animal.
- the warm-blooded animal is a human.
- the invention provides the use of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use the treatment of a bacterial infection in a warm-blooded animal.
- the bacterial infection is selected from the group consisting of community- acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections, Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococci.
- the warm-blooded animal is a human.
- the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in production of an anti-bacterial effect in a warm-blooded animal.
- the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in inhibition of bacterial DNA gyrase and/or topoisomerase IV in a warm-blooded animal.
- the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in the treatment of a bacterial infection in a warm-blooded animal.
- the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in the treatment of community- acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections, Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis or Vancomycin-Resistant Enterococci.
- alkyl includes both straight and branched chain alkyl groups.
- alkyl groups include methyl, ethyl, propyl, isopropyl and t-butyl.
- references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.
- a "heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxide(s).
- a “heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.
- a “heterocyclyl” is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen.
- heterocyclyl examples and suitable values of the term "heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, 7V-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine -TV-oxide and quinoline- ⁇ /-oxide.
- heterocyclyl is imidazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyrazolyl, 1,2,4-triazolyl, pyridyl, benzothiazolyl, isoxazolyl, pyrazinyl, pyrimidinyl and thiazolyl.
- a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH 2 - group can optionally be replaced by a -C(O)-. Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
- Suitable values for "carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
- a particular example of “carbocyclyl” is phenyl.
- An is acetoxy.
- Examples are methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
- Examples of "Ci- 4 alkoxycarbonylamino" are methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino. Examples are methoxy, ethoxy and propoxy.
- Examples are formamido, acetamido and propionylamino.
- Examples of "Ci- 4 alkylS(O)a wherein a is 0 to 2" are methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
- Examples of are propionyl and acetyl.
- Examples of 'W-(d -4 alkyl)amino are methylamino and ethylamino.
- Examples of 'W,N-(C 1-4 alkyl) 2 amino are di-N-methylamino, di-(7V-ethyl)amino and jV-ethyl-jV-methylamino.
- Examples of "C2-4alkenyl” are vinyl, allyl and 1-propenyl.
- Examples of "C 2 - 4 alkynyl” are ethynyl, 1-propynyl and 2-propynyl. Examples of
- 'W-(Ci. 4 alkyl)sulphamoyl are 7V-(methyl)sulphamoyl and 7V-(ethyl)sulphamoyl.
- Examples of " ⁇ /, ⁇ /-(Ci-4alkyl)2Sulphamoyl” are ⁇ /, ⁇ /-(dimethyl)sulphamoyl and ⁇ /-(methyl)- ⁇ /-(ethyl)sulphamoyl.
- Examples of are methylaminocarbonyl and ethylaminocarbonyl. Examples are dimethylaminocarbonyl and methylethylaminocarbonyl.
- Examples of 'W-(Ci- 4 alkoxy)carbamoyl are methoxyaminocarbonyl and isopropoxyaminocarbonyl.
- Examples of 'W-(Ci-4alkyl)- ⁇ /-(Ci-4alkoxy)carbamoyl” are ⁇ /-methyl-7V-methoxyaminocarbonyl and N-methyl-TV-ethoxyaminocarbonyl.
- Examples of 'W-(Ci. 4 alkyl)ureido" are N'-methylureido and N'-isopropylureido.
- Examples of 'W,iV-(C 1-4 alkyl) 2 ureido" are NW-dimethylureido and N'-methyl-N'-isopropylureido.
- Examples of 'W-(Ci- 4 alkyl)hydrazinocarbonyl" are N'-methylhydrazinocarbonyl and TV-isopropylhydrazinocarbonyl.
- Examples of W,N'-(Ci -4 alkyl) 2 hydrazinocarbonyl” are ⁇ W-dimethylhydrazinocarbonyl and 7V'-methyl-7V -isopropylhydrazinocarbonyl.
- Examples of "Ci -4 alkylsulphonylamino” are methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino.
- Examples of “Ci ⁇ alkylsulphonylaminocarbonyl” are methylsulphonylaminocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl. Examples are methylsulphonyl, isopropylsulphonyl and t-butylsulphonyl.
- Examples of “Cs- ⁇ Cycloalkyl” are cyclopropyl and cyclohexyl.
- Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, ⁇ -glycerophosphate, fumarate, hydrochloride, citrate, maleate, tartrate and hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid.
- suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, 7V-methylpiperidine, 7V-ethylpiperidine, procaine, dibenzylamine, 7V,7V-dibenzylethylamine, tris-(2-hydroxyethyl)amine, TV-methyl d-glucamine and amino acids such as lysine.
- the pharmaceutically-acceptable salt is the sodium salt.
- salts which are less soluble in the chosen solvent may be utilized whether pharmaceutically-acceptable or not.
- a compound of the formula (I) or (I') or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and / or topoisomerase IV and is not to be limited merely to any one tautomeric form utilized within the formulae drawings.
- the formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names.
- compounds of formula (I) or (I') may contain asymmetrically substituted carbon(s) and sulphur atom(s), and accordingly may exist in, and be isolated in, as far as those additional asymmetrically substituted carbon(s) and sulphur atom(s) are concerned, optically-active and racemic forms at those positions. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, at any additional asymmetrically substituted carbon(s) and sulphur atom(s), which possesses properties useful in the inhibition of DNA gyrase and / or topoisomerase IV.
- Optically-active forms may be prepared by procedures known in the art for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase.
- Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any polymorphic form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase and / or topoisomerase IV.
- H represents any isotopic form of hydrogen including 1 H, 2 H (D), and 3 H (T);
- C represents any isotopic form of carbon including 12 C, 13 C, and 14 C;
- O represents any isotopic form of oxygen including 16 O, 17 O and 18 O;
- N represents any isotopic form of nitrogen including 13 N, 14 N and 15 N;
- P represents any isotopic form of phosphorous including 31 P and 32 P;
- S represents any isotopic form of sulfur including 32 S and 35 S;
- F represents any isotopic form of fluorine including 19 F and 18 F;
- Cl represents any isotopic form of chlorine including 35 Cl, 37 Cl and 36 Cl; and the like.
- compounds represented by formula (I) or (I') comprise isomers of the atoms therein in their naturally occurring abundance.
- 1 H would normally be present in greater than 99.98% abundance; however, a compound of the invention can be enriched in 2 H or 3 H at one or more positions where H is present.
- R 1 is Ci -6 alkyl.
- R 1 is ethyl.
- R 2 is hydrogen.
- X 1 N-.
- X 1 C(R 6 )-.
- X 1 C(R 6 )-; wherein R 6 is hydrogen.
- X 2 and X 3 is selected from (i) and the other is selected from (ii):
- X 2 is selected from (i) and X 3 is selected from (ii):
- X 2 is -O-.
- X 2 is -S-.
- X 2 is -N(R 8 )-.
- X 2 is -C(R 9 XR 10 )-.
- X 3 is -O-.
- X 3 is -S-.
- X 3 is -N(R 8 )-.
- X 3 is -N(R 8 )-; wherein R 8 is hydrogen or
- X 3 is -N(R 8 )-; wherein R 8 is Ci -6 alkyl;
- X 3 is -N(R 8 )-; wherein R 8 is hydrogen or t-butoxycarbonyl.
- X 3 is -C(R 9 XR 10 )-.
- Ring A is carbocyclyl
- Ring A is phenyl
- Ring A and (R 4 ) n together are 4-cyanophenyl. Ring A and (R 4 ) n together are 3-cyanophenyl.
- Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 11 .
- Ring A is heterocyclyl
- Ring A is a pyridyl. Ring A is pyrid-3-yl.
- Ring A is pyrid-4-yl.
- Ring A is a thiazolyl
- Ring A is thiazol-2-yl. Ring A and (R 4 ) n together are 4-carboxy-thiazol-2-yl.
- Ring A and (R 4 ) n together are 4-carbamoyl-thiazol-2-yl.
- Ring A and (R 4 ) n together are 4-(7V-methyl-carbamoyl)-thiazol-2-yl.
- Ring A and (R 4 ) n together are 4-(ethoxycarbonyl)-thiazol-2-yl. Ring A is a triazolyl.
- Ring A is l,2,4-triazol-3-yl.
- R 3 is hydrogen
- R is a heterocyclyl, wherein said heterocyclyl may be optionally substituted on carbon by one or more R 14 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 .
- R 3 is a piperazinyl
- R 3 is piperazin-1-yl.
- R 3 is a morpholinyl
- R 3 is morpholin-4-yl.
- R 3 is a piperidinyl.
- R 3 is piperidin-1-yl.
- R 3 is pyridyl
- R 3 is pyrid-4-yl.
- R 3 is benzothiazolyl.
- R 3 is benzothiazol-2-yl.
- R 3 is a phenyl which may be optionally substituted on one or more carbon with one or more independently selected R 14 .
- R 3 is phenyl
- R 3 is 3-methyl-phenyl.
- R 3 is 4-methyl-phenyl.
- R 3 is 2-fiuoro-phenyl.
- R 3 is hydrogen
- R 3 is a heterocyclyl, wherein said heterocyclyl may be optionally substituted on carbon by one or more R 14 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 15 .
- R 3 is a piperazinyl
- R 3 is piperazin-1-yl.
- R 3 is a morpholinyl.
- R 3 is morpholin-4-yl.
- R 3 is a piperidinyl
- R 3 is piperidin-1-yl.
- R 3 is pyridyl.
- R 3 is pyrid-4-yl.
- R 3 is benzothiazolyl.
- R 3 is benzothiazol-2-yl.
- R 3 is a phenyl which may be optionally substituted on one or more carbon with one or more independently selected R 14 .
- R 3' is phenyl.
- R 3 is 3-methyl-phenyl.
- R 3 is 4-methyl-phenyl.
- R 3 is 2-fluoro-phenyl.
- R 3 is 4-(moropholinomethyl)-phenyl.
- R 4 is cyano.
- R 4 is carboxy
- R 4 is carbamoyl
- R 4 is N-methyl-carbamoyl.
- R 4 is N-ethyl-carbamoyl.
- R 4 is ethoxycarbonyl.
- n 0.
- n 1.
- R 2 is hydrogen
- X 1 C(R 6 )-; wherein R 6 is hydrogen;
- X 3 is -N(R 8 )-; wherein R 8 is hydrogen or Ci_ 6 alkoxycarbonyl; Ring A is pyridyl;
- R 3 is hydrogen; n is 0; or a pharmaceutically acceptable salt thereof.
- R 1 , R 2 , X 1 , R 3 , R 8 , Ring A, R 4 and n are as described herein above; or a pharmaceutically acceptable salt thereof.
- R 3 is H.
- ring A is pyridyl.
- R 3 is H and ring A and (R 4 ) n together are pyrid-3-yl.
- R 3 is piperazinyl and ring A together with (R 4 ) n is 4-carboxy-thiazole-2-yl, 4-carbamoyl-thiazol-2- yl or 4-ethoxycarbonyl-thiazol-2-yl.
- R 3 is morpholino and ring A together with (R 4 ) n is 4-carboxy-thiazole-2-yl, 4-(N-methyl- carbamoyl)-thiazol-2-yl, or 4-ethoxycarbonyl-thiazol-2-yl.
- R 8 is H or methyl.
- R 3 is piperdinyl and ring A together with (R 4 ) n is l,2,4-triazol-3-yl, 4-carboxy-thiazole-2-yl, 4-(N-methyl-carbamoyl)- thiazol-2-yl, or 4-carbamoyl-thiazol-2-yl.
- R 3 is phenyl, 3-methylphenyl, 4-methylphenyl, or 2-fluorophenyl and ring A together with (R 4 ) n is l,2,4-triazol-3-yl, 4-carboxy-thiazole-2-yl, 4-(N-methyl-carbamoyl)-thiazol-2-yl, or 4- ethoxycarbonyl-thiazol-2-yl.
- R 1 , R 2 , X 1 , R 3 , Ring A, R 4 and n are as described herein above; or a pharmaceutically acceptable salt thereof.
- R 3 is H
- ring A together with (R 4 ) n is pyrid-3yl, pyrid-4-yl, 3-cyano-phenyl, or 4-cyanophenyl.
- a compound of formula (I') which is a compound of formula (IC):
- R 1 , R 2 , X 1 , R 3 , Ring A, R 4 and n are as described herein above; or a pharmaceutically acceptable salt thereof.
- R 3 is pyrid-4-yl and ring A together with (R 4 ) n is 4-carboxy-thiazole-2-yl or 4-ethoxycarbonyl-thiazol-2-yl.
- R 3 ' is benzothiazol-2-yl and ring A together with (R 4 ) n is 4- carboxy-thiazole-2-yl, 4-(N-methyl-carbamoyl)-thiazol-2-yl, or 4-ethoxycarbonyl-thiazol-2- yl.
- R 3 ' is 4-(morpholinomethyl)-phenyl, and ring A together with (R 4 ) n is 4-carboxy-thiazole-2-yl or 4-ethoxycarbonyl-thiazol-2-yl.
- R 3 ' is phenyl and ring A together with (R 4 ) n is 4- ethoxycarbonyl-thiazol-2-yl.
- Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention.
- the present invention also comprises any two or more compounds of the Examples.
- the present invention provides a process for preparing a compound of formula (I) or (I') or a pharmaceutically-acceptable salt thereof.
- the present invention also provides that the compounds of the formula (I) or (I') and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated): Process a) reacting an amine of formula (II):
- L is a displaceable group. Suitable values for L include chloro, bromo, tosyl and trifluoromethylsulphonyloxy.
- M is an organometallic reagent
- suitable values for M include organoboron and organotin reagents, in particular B(OR Z ) 2 where R z is hydrogen or C ⁇ aUcyl for example B(OH) 2 ; and Sn(R y ) 3 where R y is Ci -6 alkyl for example Sn(Bu) 3 .
- Process a) and Process b) Amines and acids may be coupled together in the presence of a suitable coupling reagent.
- Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole (CDI) and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di- ⁇ /Ay/-pyridines such as 2,6-lutidine or
- Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide.
- the coupling reaction may conveniently be performed at a temperature in the range of -40 to 40 0 C.
- Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters.
- the reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40 0 C.
- Compounds of formula (III) may be prepared according to the following scheme:
- L' is CN, CHO, CO 2 H or COCl.
- Compounds of formula (V) can be prepared in a likewise manner.
- Process ⁇ Formation of a thiazole-2-yl ring A can be carried out by heating a compound of formula (X) or formula (X') with a compound of formula (XI) in a suitable polar solvent such as an alcohol.
- Compounds of formula (X) or (X') can be prepared by reacting a compound of formula (XI) or (XI'), respectively, with ammonium sulphide in a suitable polar solvent such as an alcohol, typically, with the addition of heat.
- a suitable polar solvent such as an alcohol
- R 3 or R 3 is an amine, such as -NH 2 , N- alkyl amine, N,N-dialkylamine or a non-aromatic heterocycle comprising at least one secondary nitrogen ring member
- R 3 or R 3 is an amine, such as -NH 2 , N- alkyl amine, N,N-dialkylamine or a non-aromatic heterocycle comprising at least one secondary nitrogen ring member
- R and R are each independently hydrogen, a Ci_ 6 alkyl, or R and R together with the nitrogen to which they are attached form a heterocycle.
- a compound of formula (XIa) can be prepared by reacting 2-amino-6-chloro-9- methyl-9H-purine-8-carbonitrile (see J Chem Soc, Perkin Trans I, 1977, 1003 for preparation) with an isocyanate derivative in a manner analogous to that described for Process c).
- Process g): Formation of a l,2,4-triazol-3-yl ring A can be carried out by heating a compound of formula (XI) or formula (XF) in the presence of hydrazine and a compound of formula (XIII).
- a compound of formula (XIII) is formic acid it may be used as the solvent for the reaction.
- Process h Compounds of formula (I) or (I') in which R 3 or R 3 is hydrogen may be reacted with a compound of formula (XIV) or (XIV) by coupling chemistry utilizing an appropriate catalyst.
- Such reactions are well known in the art. For example, Pd(PPh 3 ) 4 and a suitable base such as sodium carbonate can be utilized. The reactions take place in suitable solvents and may require thermal conditions.
- Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents, oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings.
- the reagents and reaction conditions for such procedures are well known in the chemical art.
- aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group.
- modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
- the skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products. If not commercially available, the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples.
- a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl.
- an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.
- a suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
- the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
- a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid
- an arylmethoxycarbonyl group such as a benzyloxycarbonyl group
- a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.
- a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or for example, an allyl group which may be removed, for example, by use of a palladium catalyst such as palladium acetate.
- the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.
- Optically active forms of a compound of the invention may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.
- an optically active starting material formed, for example, by asymmetric induction of a suitable reaction step
- Resolution of a racemic form of the compound or intermediate using a standard procedure
- chromatographic separation of diastereoisomers when produced.
- Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.
- a pure regioisomer of a compound of the invention it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioiso
- Enzyme Potency Testing Methods Compounds may be tested for inhibition of GyrB ATPase activity using an ammonium molybdate/malachite green-based phosphate detection assay (Lanzetta, P. A., L. J. Alvarez, P. S. Reinach, and O. A. Candia, 1979, 100: 95-97).
- Assays can be performed in multiwell plates in 100 ⁇ l reactions containing: 50 mM HEPES buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1 ,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 5 ⁇ g/ml sheared salmon sperm DNA, 2.5 nM E. coli GyrA, 2.5 nM E. coli GyrB, 250 ⁇ M ATP, and compound in dimethylsulfoxide.
- Reactions can be quenched with 150 ⁇ l of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium mo lybdate tetrahydrate, and 1 M hydrochloric acid. Plates can be read in an absorbance plate reader at 650 nm and percent inhibition values may be calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 ⁇ M) reactions as 100% inhibition controls. Compound potency can be based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations. Inhibition of E. coli GyrA and/or GyrB can be assessed by observing percent inhibition at a given compound concentration.
- Compounds may be tested for inhibition of topoisomerase IV ATPase activity as described above for GyrB except the lOO ⁇ l reactions may contain the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM 1,4-dithio-DL-threitol, 0.005% Brij-35, 5 ⁇ g/ml sheared salmon sperm DNA, 2.5 nM Streptococcus pneumoniae ParE, 160 ⁇ M ATP, and compound in dimethylsulfoxide.
- Compound potency may be based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations.
- Compound activity against S. pneumoniae can be assessed by observing percent inhibition at a given compound concentration.
- Inhibition of S. pneumoniae ParE can be assessed by observing percent inhibition at a given compound concentration.
- Compounds may be tested for inhibition of topoisomerase IV ATPase activity as described above for GyrB except the 30 ⁇ l reactions contained the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM 1,4- Dithio-DL-threitol, 0.005% Brij-35, 5 ⁇ g/ml sheared salmon sperm DNA, 1.25 nM S. pneumoniae ParE, 160 ⁇ M ATP, and compound in dimethylsulfoxide.
- Compound potency may be based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations. Inhibition of S.
- pneumoniae ParE can be assessed by observing percent inhibition at a given compound concentration. Compounds in the following table were tested in an assay substantially similar to the assay described in this paragraph to determine percent inhibition of S. pneumoniae ParE at a compound concentration of 50 ⁇ M:
- compounds of the invention have IC50 values of ⁇ 200 ⁇ M in one or both assays described herein above.
- Example 1 showed an IC50 of 20.2 ⁇ M against Streptococcus pneumoniae ParE.
- the compounds in Table A have IC50 values of >200 ⁇ M against Streptococcus pneumoniae ParE.
- Compounds may be tested for antimicrobial activity by susceptibility testing in liquid media.
- Compounds may be dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays.
- the organisms used in the assay may be grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism.
- the suspension can be a 0.5 McFarland and a further 1 in 10 dilution can be made into the same liquid medium to prepare the final organism suspension in 100 ⁇ L. Plates can be incubated under appropriate conditions at 37 0 C for 24 hrs prior to reading.
- the Minimum Inhibitory Concentration (MIC) may be determined as the lowest drug concentration able to reduce growth by 80% or more.
- a compound of the formula (I) or (I'), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
- compounds of the present invention inhibit bacterial DNA gyrase and / or topoisomerase IV and are therefore of interest for their antibacterial effects.
- the compounds of the invention inhibit bacterial DNA gyrase and are therefore of interest for their antibacterial effects.
- the compounds of the invention inhibit topoisomerase IV and are therefore of interest for their antibacterial effects.
- the compounds of the invention inhibit both DNA gyrase and topoisomerase IV and are therefore of interest for their antibacterial effects.
- infection or “bacterial infection” refers to a gynecological infection.
- infection or “bacterial infection” refers to a respiratory tract infection (RTI).
- RTI respiratory tract infection
- infection or “bacterial infection” refers to a sexually transmitted disease.
- infection or “bacterial infection” refers to a urinary tract infection.
- infection or “bacterial infection” refers to acute exacerbation of chronic bronchitis (ACEB).
- infection or “bacterial infection” refers to acute otitis media.
- infection refers to acute sinusitis. In one aspect of the invention “infection” or “bacterial infection” refers to an infection caused by drug resistant bacteria. In one aspect of the invention “infection” or “bacterial infection” refers to catheter-related sepsis. In one aspect of the invention “infection” or “bacterial infection” refers to chancroid. In one aspect of the invention “infection” or “bacterial infection” refers to chlamydia. In one aspect of the invention
- infection or “bacterial infection” refers to community-acquired pneumonia (CAP).
- infection or “bacterial infection” refers to complicated skin and skin structure infection.
- infection or “bacterial infection” refers to uncomplicated skin and skin structure infection.
- infection or “bacterial infection” refers to endocarditis.
- infection or “bacterial infection” refers to febrile neutropenia.
- infection or “bacterial infection” refers to gonococcal cervicitis.
- infection or “bacterial infection” refers to gonococcal urethritis.
- infection refers to hospital-acquired pneumonia (HAP). In one aspect of the invention “infection” or “bacterial infection” refers to osteomyelitis. In one aspect of the invention “infection” or “bacterial infection” refers to sepsis. In one aspect of the invention “infection” or “bacterial infection” refers to syphilis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Acinetobacter baumanii. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Acinetobacter haemolyticus .
- an “infection” or “bacterial infection” refers to an infection caused by Acinetobacter junii. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Acinetobacter johnsonii. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Acinetobacter Iwoffi. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by B acteroides bivius. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by B acteroides fragilis.
- an “infection” or “bacterial infection” refers to an infection caused by Burkholderia cepacia. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Campylobacter jejuni. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Chlamydia pneumoniae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Chlamydia urealyticus. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Chlamydophila pneumoniae.
- an “infection” or “bacterial infection” refers to an infection caused by Clostridium difficili. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Enterobacter aerogenes. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Enterobacter cloacae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Enterococcus faecalis . In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Enterococcus faecium.
- an “infection” or “bacterial infection” refers to an infection caused by Escherichia coli. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Gardnerella vaginalis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Haemophilus par ainfiuenzae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Haemophilus influenzae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Helicobacter pylori.
- an “infection” or “bacterial infection” refers to an infection caused by Klebsiella pneumoniae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Legionella pneumophila. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by
- an “infection” or “bacterial infection” refers to an infection caused by Methicillin-susceptible Staphylococcus aureus. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Moraxella catarrhalis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Morganella morganii. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Mycoplasma pneumoniae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by N ' eisseria gonorrhoeae.
- an “infection” or “bacterial infection” refers to an infection caused by Penicillin- resistant Streptococcus pneumoniae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Penicillin-susceptible Streptococcus pneumoniae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus magnus. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus micros. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by
- an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus asaccharolyticus . In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus prevotii. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus tetradius. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus vaginalis.
- an “infection” or “bacterial infection” refers to an infection caused by Proteus mirabilis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Pseudomonas aeruginosa. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Quinolone-Resistant Staphylococcus aureus. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Quinolone-Resistant Staphylococcus epidermis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Salmonella typhi.
- an “infection” or “bacterial infection” refers to an infection caused by Salmonella paratyphi. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Salmonella enteritidis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Salmonella typhimurium. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Serratia marcescens. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Staphylococcus aureus. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Staphylococcus epidermidis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by
- an "infection” or “bacterial infection” refers to an infection caused by Streptococcus agalactiae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Streptococcus pneumoniae. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Streptococcus pyogenes. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Stenotrophomonas maltophilia. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Ureaplasma urealyticum.
- an “infection” or “bacterial infection” refers to an infection caused by Vancomycin-Resistant Enter ococcus faecium. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by
- an “infection” or “bacterial infection” refers to an infection caused by Vancomycin-Resistant Staphylococcus aureus. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Vancomycin-Resistant Staphylococcus epidermis. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Acinetobacter spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Bacteroides spp..
- an “infection” or “bacterial infection” refers to an infection caused by Burkholderia spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Campylobacter spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Chlamydia spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Chlamydophila spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Clostridium spp..
- an "infection” or “bacterial infection” refers to an infection caused by Enterobacter spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Enterococcus spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Escherichia spp.. In one aspect of the invention an “infection” or
- bacterial infection refers to an infection caused by Gardnerella spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Haemophilus spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Helicobacter spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Klebsiella spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Legionella spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Moraxella spp..
- an “infection” or “bacterial infection” refers to an infection caused by Morganella spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Mycoplasma spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Neisseria spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Peptostreptococcus spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Proteus spp..
- an “infection” or “bacterial infection” refers to an infection caused by Pseudomonas spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Salmonella spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Serratia spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Staphylococcus spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Strep toccocus spp..
- an “infection” or “bacterial infection” refers to an infection caused by Stenotrophomonas spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by Ureaplasma spp.. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by aerobes. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by obligate anaerobes. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by facultative anaerobes. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by gram-positive bacteria.
- an “infection” or “bacterial infection” refers to an infection caused by gram-negative bacteria. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by gram- variable bacteria. In one aspect of the invention an “infection” or “bacterial infection” refers to an infection caused by atypical respiratory pathogens.
- a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.
- a method for inhibition of bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal, such as a human being in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof as defined hereinbefore.
- a method of treating a bacterial infection in a warm-blooded animal which comprises administering to said animal an effective amount of a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof as defined hereinbefore.
- a method of treating a bacterial infection selected from a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and /or syphilis in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or (I') or a
- a further feature of the present invention is a compound of formula (I) or (I') and pharmaceutically acceptable salts thereof for use as a medicament.
- the medicament is an antibacterial agent.
- a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
- a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal such as a human being.
- a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a bacterial infection selected from a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and / or syphilis in a warm-blooded animal such as a human being.
- a bacterial infection selected from a gynec
- a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
- a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
- a bacterial infection selected from a gynecological infection, a respiratory
- the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or (I') or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
- a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in a warm-blooded animal, such as a human being.
- a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal, such as a human being.
- a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in a warm-blooded animal, such as a human being.
- a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and/or syphilis in a warm-blooded animal,
- RTI respiratory tract infection
- compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).
- the compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
- compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and
- Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.
- inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate
- granulating and disintegrating agents such as corn starch or algenic acid
- binding agents such as starch
- lubricating agents
- Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil such as peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol
- the aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin).
- the oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.
- the pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions.
- the oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these.
- Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening, flavouring and preservative agents.
- Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.
- the pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above.
- a sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
- Compositions for administration by inhalation may be in the form of a conventional pressurized aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets.
- Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
- the amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
- a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
- Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient.
- the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
- a daily dose in the range of 1-50 mg/kg is employed.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- one embodiment of the present invention is directed to treating or preventing diseases caused by bacterial infections, wherein the bacteria comprise a GyrB ATPase or topoisomerase IV ATPase enzyme.
- Treating a subject with a disease caused by a bacterial infection includes achieving, partially or substantially, one or more of the following: the reducing or amelioration of the progression, severity and/or duration of the infection, arresting the spread of an infection, ameliorating or improving a clinical symptom or indicator associated with a the infection (such as tissue or serum components), and preventing the reoccurrence of the infection.
- preventing a bacterial infection refers to the reduction in the risk of acquiring the infection, or the reduction or inhibition of the recurrence of the infection.
- a compound of the invention is administered as a preventative measure to a patient, preferably a human, before a surgical procedure is preformed on the patient to prevent infection.
- the term "effective amount" refers to an amount of a compound of this invention for treating or preventing a bacterial infection is an amount which is sufficient to prevent the onset of an infection, reduce or ameliorate the severity, duration, or progression, of an infection, prevent the advancement of an infection, cause the regression of an infection, prevent the recurrence, development, onset or progression of a symptom associated with an infection, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
- compounds of formula (I) or (I') and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in- vitro and in- vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase and / or topoisomerase IV in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- Suitable classes and substances may be selected from one or more of the following: i) other antibacterial agents for example macrolides e.g. erythromycin, azithromycin or clarithromycin; quinolones e.g. ciprofloxacin or levofloxacin; ⁇ -lactams e.g. penicillins e.g.
- amoxicillin or piperacillin cephalosporins e.g. ceftriaxone or ceftazidime
- carbapenems e.g. meropenem or imipenem etc
- aminoglycosides e.g. gentamicin or tobramycin; or oxazolidinones
- anti-infective agents for example, an antifungal triazole e.g. or amphotericin
- biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products; and/or iv) efflux pump inhibitors.
- a chemotherapeutic agent selected from: i) one or more additional antibacterial agents; and/or ii) one or more anti-infective agents; and/or iii) biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products; and/or iv) one or more efflux pump inhibitors.
- fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected or using Agilent 1 lOOseries LC/MSD equipped with Sedex 75ELSD, run in atmospheric pressure chemical ionization mode and, where appropriate, either positive ion data or negative ion data were collected; mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe; where indicated ionization was effected by electron impact (EI), fast atom bombardment (FAB) or electrospray (ES); values for m/z are given; generally, only ions which indicate the parent mass are reported;
- EI electron impact
- FAB fast atom bombardment
- ES electrospray
- each intermediate was generally purified to the standard required for the subsequent stage and was characterized in sufficient detail to confirm that the assigned structure was correct; purity was assessed by high pressure liquid chromatography, thin layer chromatography, or NMR and identity was determined by infra-red spectroscopy (IR), mass spectroscopy or NMR spectroscopy as appropriate; (vii) the following abbreviations may be used: DMSO is dimethylsulfoxide; CDCI 3 is deuterated chloroform; MS is mass spectroscopy; EtOAc is ethyl acetate;
- EDC is N-(3-dimethylaminopropyl)-N-ethylcarbodiimide
- HATU is 2-(lH-7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyl uronium hexafluorophosphate methanaminium
- OAc is acetate
- THF is tetrahydrofuran
- MeOH is methanol
- TFA trifluoroacetic acid
- Xantphos is 4,5-bis(diphenylphosphino)-9,9-dimethyl-xanthene
- the reaction mixture was then refluxed at 100 0 C for 14 h, then cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (3x10 mL). The combine extracts were washed with water (20 mL) and brine, then dried over anhydrous sodium sulphate and concentrated to a residue. The residue was subjected to column chromatography (silica, chloroform-methanol) to yield the title compound.
- DMSO-d fi ⁇ 1.17 (t, 3H), 3.72 (t, 4H), 3.26 (q, 2H), 4.11 (s, 3H), 4.20 (br s, 4H), 7.74 (s, IH), 7.90 (s, IH), 8.36 (s, IH), 9.03 (t, IH), 9.08 (s, IH).
- DMSO-d ⁇ ⁇ 1.25 (t, 3H), 2.50 (s, 3H), 2.87 (d, 3H), 3.30 (q, 2H), 4.25 (s, 3H), 7.54 (m, 2H), 8.58 (m, 3H), 9.11 (br s, IH), 9.77 (br s, IH).
- DMSOd n ⁇ 1.162 (t, 3H), ⁇ 1.35 (t, 3H), ⁇ 3.286 (q, 2H), ⁇ 4.195 (s, 3H), ⁇ 4.38 (q, 2H), ⁇ 7.49 (m, 2H), ⁇ 7.68 (m, IH), ⁇ 8.27 (t, IH), ⁇ 8.77 (s, IH), ⁇ 9.21 (t, IH), ⁇ 9.21 (t, IH), ⁇ 9.85 (s, IH).
- DMSO-d ⁇ ⁇ 1.16 (t, 3H), ⁇ 1.65-1.694 (m, 6H), ⁇ 3.269 (q, 2H), ⁇ 4.077 (s, 3H), ⁇ 4.25 (bs, 4H), ⁇ 8.568 (s, IH), ⁇ 8.94 (s, IH), ⁇ 9.28 (s, IH).
- Examples 28-30 The following Examples were prepared by the procedure described in Example 27 from the starting materials (SM) indicated.
- the reaction slurry was heated to 6O 0 C for 1 hour.
- Sodium borohydride (0.544 g, 14.40 mmol) was added in a single portion, and the reaction was heated for an additional 12 hours.
- the progress of the reaction was monitored by LC/MS.
- the solvent was removed by rotary evaporation.
- the solid was dissolved in EtOAc and water.
- the mixture was neutralized with K 2 CO 3 while cooling the mixture in an ice bath.
- the tin salts precipitated from solution and were removed by filtering the mixture though a pad of Celite.
- 6-Chloropyridine-2,3-diamine (Intermediate 1, 2.4 g, 16.72 mmol) was dissolved in MeOH (20 mL). Nicotinaldehyde (1.584 mL, 16.72 mmol) was added in a single portion and the reaction was heated to 6O 0 C. Upon reacting, the solution turned red, and LC/MS showed that the condensation product ([M+H] + : 233, 235 for C 11 H 9 CIN4) had formed. The reflux condenser was removed, and the saturated product was aromatized by heating the solution in the presence of air for 4 days. Upon cooling and concentrating a precipitate formed.
- DMSOd n ⁇ 1.16 (t, 3H), 1.437 (s, 9H), 3.076 (t, 2H), 3.239 (m, 2H), 3.48-3.64 (m, 4H), 4.004 (s, 3H), 4.45 (br s, 2H), 8.94 (br t, IH), 9.1 (br s, IH), 9.8 (br s, IH), 10.04 (br s, IH).
- DMSO-c ⁇ ⁇ 1.14 (t, 3H), ⁇ 1.60-1.67 (m, 6H), ⁇ 3.23 (q, 2H), ⁇ 3.762 (s, 3H), ⁇ 3.88 (brs, 2H), ⁇ 4.42 (brs, 2H), ⁇ 8.91 (s, IH).
- Argon gas was purged through a mixture of l-(6-chloro-8-cyano-9-methyl-9H-purin-2-yl)-3- ethyl-urea (Intermediate 19, 100 mg, 0.3577 mmol) in toluene (5 mL) for 15 min, then palladium acetate (6.97 mg, 0.0311 mmol), tri-o-tolylphosphine (24 mg, 0.0789 mmol), potassium phosphate (151.6 mg, 0.715 mmol) were added. The reaction mixture was again purged with argon gas for 10 min and phenylboronic acid (86.5 mg, 0.7148 mmol) was added and the mixture was heated to 80 0 C for 6 h.
- reaction mixture was cooled to room temperature, then passed through a celite bed.
- the filtrate was concentrated under reduced pressure to obtain a residue which was stirred in diethyl ether for 10-20 min.
- the solid which formed was collected by filtration and dried to afford 70 mg (60%) of l-(8-cyano-9-methyl-6- phenyl-9H-purin-2-yl)-3-ethylurea.
- reaction mixture was heated to 100 0 C for 18 h. After completion of the reaction, the reaction mixture was concentrated to dryness. Water (10 mL) was added to the residue and the suspension that formed was stirred for 20 min. The suspension was filtered and the solid was co-distilled with toluene (2 x 20 mL) to afford 1.05 g (75%) of l-(8-cyano-9-methyl-6- piperidin-l-yl-9H-purin-2-yl)-3 -ethyl-urea as solid.
- Phosphorus oxychloride (93 mL, 1020.54 mmol) was cooled to 5 0 C using an ice bath. Dry DMF (35 mL) was added slowly with stirring over 30 min to the phosphorus oxychloride. A white precipitate formed during the addition. The reaction mixture was gently warmed (45 0 C) to dissolve the precipitate and produce a clear solution to which was added 2- aminopyrimidine-4,6-diol (24.2 g, 190.40 mmol) in small portions over 1 h, then the mixture was heated at 8O 0 C. The reaction mixture turned a dark red-brown color. After 12 hours, the reaction mixture was cooled to room temperature and excess POCl ⁇ was removed by rotary evaporation.
- ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate (Intermediate 31, 1 g, 3.88 mmol), pyridin-4-ylboronic acid (0.636 g, 4.66 mmol) and sodium carbonate (0.494 g, 4.66 mmol) were combined and suspended in a 4:1 mixture of dioxane and water.
- Pd(PPh 3 ) 4 (0.224 g, 0.19 mmol) was added in a single portion.
- the vessel was sealed and heated to 15O 0 C in the microwave for 30 min.
- the reaction mixture was diluted with water and methanol, then filtered through a pad of Celite to remove the palladium salts.
- ethyl 2-amino-4-(pyridin-4-yl)thieno[2,3-d]pyrimidine-6- carboxylate (Intermediate 32, 300 mg, 1.00 mmol), ethyl isocyanate (0.785 mL, 9.99 mmol) and dibutyltin diacetate (2.68 ⁇ L, 9.99 ⁇ mol) were combined and suspended in a 1:1 mixture of THF and toluene.
- the vessel was sealed and heated to 14O 0 C in the microwave for 60 min.
- the reaction mixture was diluted with ethyl acetate and washed with water and brine.
- the organic phase was dried over Na2SO ⁇ filter and concentrate, then purified by flash column chromatography (0-100% EtOAc / hexanes) to afford the title compound.
Abstract
Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
Description
5-6-BICYCLIC HETEROAROMATIC COMPOUNDS WITH ANTIBACTERIAL ACTIVITY
Field of the Invention
The present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.
Background of the Invention
The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiple resistant Enter ococcus faecium.
The preferred clinically effective antibiotic for treatment of last resort of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β-lactams, quinolones and macrolides used for the treatment of upper respiratory tract
infections, also caused by certain Gram negative strains including H. influenzae and M. catarrhalis.
Consequently, in order to overcome the threat of widespread multi-drug resistant organisms, there is an on-going need to develop new antibiotics, particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups.
Deoxyribonucleic acid (DNA) gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA. DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA. The enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A2B2 tetrameric complex. The A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage. The B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.
Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109).
DNA gyrase is a well-validated target of antibacterials, including the quinolones and the coumarins. The quinolones {e.g. ciprofloxacin) are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol.
Rev. 61: 377-392). Members of this class of antibacterials also inhibit topoisomerase IV and as a result, the primary target of these compounds varies among species. Although the quinolones are successful antibacterials, resistance generated by mutations in the target (DNA
gyrase and topoisomerase IV) is becoming an increasing problem in several organisms, including S. aureus and Streptococcus pneumoniae (Hooper, D. C, 2002, The Lancet Infectious Diseases 2: 530-538). In addition, quinolones, as a chemical class, suffer from toxic side effects, including arthropathy that prevents their use in children (Lipsky, B. A. and Baker, C. A., 1999, Clin. Infect. Dis. 28: 352-364). Furthermore, the potential for cardiotoxicity, as predicted by prolongation of the QTC interval, has been cited as a toxicity concern for quinolones.
There are several known natural product inhibitors of DNA gyrase that compete with ATP for binding the GyrB subunit (Maxwell, A. and Lawson, D. M. 2003, Curr. Topics in Med. Chem. 3: 283-303). The coumarins are natural products isolated from Streptomyces spp., examples of which are novobiocin, chlorobiocin and coumermycin Al. Although these compounds are potent inhibitors of DNA gyrase, their therapeutic utility is limited due to toxicity in eukaryotes and poor penetration in Gram-negative bacteria (Maxwell, A. 1997, Trends Microbiol. 5: 102-109). Another natural product class of compounds that targets the GyrB subunit is the cyclothialidines, which are isolated from Streptomyces filipensis
(Watanabe, J. et al 1994, J. Antibiot. 47: 32-36). Despite potent activity against DNA gyrase, cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).
Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomerase IV are known in the art. For example, coumarin-containing compounds are described in patent application number WO 99/35155, 5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879, and pyrazole compounds are described in patent application WO 01/52845 (US patent US6,608,087). AstraZeneca has also published certain applications describing anti-bacterial compounds: WO2005/026149, WO2006/087544, WO2006/087548, WO2006/087543, WO2006/092599, WO2006/092608, WO2007/071965, WO2008/020227, WO2008/020222, WO2008/020229, and WO2008/068470.
Summary of the Invention
We have discovered a new class of compounds which are useful for inhibiting DNA gyrase and / or topoisomerase IV. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.
According to the present invention there is provided a compound of formula (I):
- A -
(I)
R1 is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more R5; R2 is selected from hydrogen or Ci_6alkyl; wherein said
may be optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, nitro and amino;
X1 is selected from =N- or =C(R6)-; X2 and X3 are independently selected from (i) or (ii): (i) -N= or -C(R7)=;
(ii) -O-, -S-, -N(R8)- or -C(R9)(R10)-; wherein X2 and X3 are not both selected from (i);
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R11; R3, R6, R7, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci_6alkyl, C2-6alkenyl, C2-6alkynyl,
Ci_6alkanoyl, Ci_6alkanoyloxy, 7V-(Ci-6alkyl)amino, Λ/,N-(Ci-6alkyl)2amino, Ci.6alkanoylamino, Λ/-(Ci-6alkyl)carbamoyl, Λ/,Λ/-(Ci-6alkyl)2carbamoyl, Λ/-(Ci.6alkoxy)carbamoyl, Λ/,Λ/-(Ci.6alkoxy)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, Ci-όalkoxycarbonylamino,
jV,jV-(Ci-6alkyl)2Sulphamoyl, Ci-6alkylsulphonylamino, carbocyclyl-R12- or heterocyclyl-R13-; wherein R3, R6, R7, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R14; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
R4 is a substituent on carbon is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^alkyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy,
Λ/-(Ci.6alkyl)amino,
Λ/,Λ/-(Ci.6alkyl)2carbamoyl,
Λ/-(Ci-6alkoxy)carbamoyl, Λ/,Λ/-(Ci-6alkoxy)2Carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, Ci-όalkoxycarbonylamino, Λ/-(Ci-6alkyl)sulphamoyl, Λ/,N-(Ci-6alkyl)2Sulphamoyl, d-όalkylsulphonylamino, carbocyclyl-R16- or heterocyclyl-R17-; wherein R4 may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; n is 0-4; wherein the values of R4 may be the same or different;
R5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl,
Ci_6alkanoyl, Ci_6alkanoyloxy, Λ/-(Ci-6alkyl)amino,
Ci.6alkanoylamino and C3_6cycloalkyl;
R8 is selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, Ci-6alkanoyl, Ci_6alkylsulphonyl, Ci_6alkoxycarbonyl, carbamoyl, TV-(C i-6alkyl)carbamoyl, Λ/,Λ/-(Ci.6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R12, R13, R16 and R17are independent selected from a direct bond, -O-, -N(R20)-, -C(O)-, -N(R21)C(O)-, -C(O)N(R22)-, -S(O)8-, -SO2N(R23)- or -N(R24)SO2-; wherein R20, R21, R22, R23 and R24 are independently selected from hydrogen or
and s is 0-2; and
Rπ, R15 and R19 are independently selected from Ci_6alkyl, C3_6cycloalkyl, Ci-6alkanoyl, Ci-όalkylsulphonyl, Ci-όalkoxycarbonyl, carbamoyl, Λ/-(Ci-6alkyl)carbamoyl, Λ/,Λ/-(Ci.6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R14 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylamino, acetylamino, Λ/-methylcarbamoyl, iV-ethylcarbamoyl, Λ/,Λ/-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, 7V-methyl-7V-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, 7V-methylsulphamoyl, 7V-ethylsulphamoyl, Λ/,Λ/-dimethylsulphamoyl, Λ/,Λ/-diethylsulphamoyl or TV-methyl-TV-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof.
(I')
R1, R2, R4, X1, X2, X3, ring A and n are as defined in formula (I); R3 is selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C^aUcyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, Ci_6alkanoyl, Ci_6alkanoyloxy, Λ/-(Ci-6alkyl)amino, Λ/,Λ/-(Ci-6alkyl)2amino,
Λ/,Λ/-(Ci.6alkyl)2carbamoyl, Λ/-(Ci-6alkoxy)carbamoyl, 7V>7V-(Ci-6alkoxy)2Carbamoyl, Ci.6alkylS(0)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, Ci-όalkoxycarbonylamino, Λ/-(Ci-6alkyl)sulphamoyl, Λ/,Λ/-(Ci-6alkyl)2sulphamoyl, d-όalkylsulphonylamino, carbocyclyl-R12- or heterocyclyl-R13-; wherein R3 may be optionally substituted on carbon by one or more R14 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15; wherein R12, R13 and R15 are defined as for formula (I); and
R14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifiuoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dime thy lamino, diethylamino, 7V-methyl-7V-ethylamino, acetylamino, 7V-methylcarbamoyl, JV-ethylcarbamoyl, ΛζiV-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, TV-methyl-TV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, 7V-methylsulphamoyl, 7V-ethylsulphamoyl, 7V,7V-dimethylsulphamoyl, 7V,7V-diethylsulphamoyl, jV-methyl-jV-ethylsulphamoyl, and morpholinomethyl.
For the avoidance of doubt, when X2 is selected from -N= or -C(R7)=; the bond between the -C(X2)- and the -C(Ring A)- in formula (I) or (I') is a double bond; when X2 is selected from -O-, -S-, -N(R8)- or -C(R9)(R10)-, the bond between -C(X2)- and -C(Ring A)- in formula (I) or (I') is a single bond; when X3 is selected from -N= or -C(R7)= the bond between -C(Ring A)- and -C(X3)- in formula (I) or (I') is a double bond; and when X3 is selected -O-, -S-, -N(R8)- or -C(R9)(R10)-, the bond between -C(Ring A)- and -C(X3)- in formula (I) or (I') is a single bond.
Furthermore, X2 and X3 are not both selected from (i) because the bond between -C(X2)- and -C(Ring A)- and the bond between -C(Ring A)- and -C(X3)- in formula (I) or (V) cannot both be double bonds.
In addition, when X2 and X3 are both selected from (ii) and the bond between -C(X2)- and -C(Ring A)- and the bond between -C(Ring A)- and -C(X3)- in formula (I) or (I') are both single bonds the carbon attached to Ring A has an additional hydrogen on it. For example as shown:
In one embodiment, the compounds represented by formula (I) or (I') do not include the compounds in Table A.
In another embodiment, the invention provides pharmaceutical compositions comprising a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In another embodiment, the invention provides a method of inhibiting bacterial DNA gyrase and/or bacterial topoisomerase IV in a warm-blooded animal in need of such treatment, comprising administering to the animal an effective amount of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof. In a particular embodiment, the warm-blooded animal is a human. In another embodiment, the invention provides a method of producing an antibacterial effect in a warm-blooded animal in need of such treatment, comprising administering to the animal an effective amount of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof. In a particular embodiment, the warm-blooded animal is a human. In another embodiment, the invention provides a method of treating a bacterial infection in a warm-blooded animal in need thereof, comprising administering to the animal an effective amount of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof. In a particular embodiment, the warm-blooded animal is a human. In one embodiment, the bacterial infection is selected from the group consisting of community-
acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections and infections caused by drug resistant bacteria such as Penicillin-resistant Streptococcus pneumoniae, methicillin- resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and
Vancomycin-Resistant Enterococci. In a particular embodiment, the warm-blooded animal is a human.
In another embodiment, the invention provides the use of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the production of an antibacterial effect in a warm-blooded animal. In a particular embodiment, the warm-blooded animal is a human.
In another embodiment, the invention provides the use of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomerase IV in a warm- blooded animal. In a particular embodiment, the warm-blooded animal is a human.
In another embodiment, the invention provides the use of a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use the treatment of a bacterial infection in a warm-blooded animal. In one embodiment, the bacterial infection is selected from the group consisting of community- acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections, Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococci. In a particular embodiment, the warm-blooded animal is a human.
In another embodiment, the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in production of an anti-bacterial effect in a warm-blooded animal.
In another embodiment, the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in inhibition of bacterial DNA gyrase and/or topoisomerase IV in a warm-blooded animal.
In another embodiment, the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in the treatment of a bacterial infection in a warm-blooded animal.
In another embodiment, the invention provides a compound represented by formula (I) or (I'), or a pharmaceutically acceptable salt thereof, for use in the treatment of community- acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections, Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis or Vancomycin-Resistant Enterococci.
Detailed Description of the Invention
In this specification the term alkyl includes both straight and branched chain alkyl groups. For example,
includes methyl, ethyl, propyl, isopropyl and t-butyl. However references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.
Where optional substituents are chosen from one or more groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxide(s). In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. In a further aspect of the invention a "heterocyclyl" is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl,
3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, 7V-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine -TV-oxide and quinoline-Λ/-oxide. Further examples and suitable values of the term "heterocyclyl" are imidazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyrazolyl, 1,2,4-triazolyl, pyridyl, benzothiazolyl, isoxazolyl, pyrazinyl, pyrimidinyl and thiazolyl.
A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH2- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. A particular example of "carbocyclyl" is phenyl.
An
is acetoxy. Examples
are methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "Ci-4alkoxycarbonylamino" are methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino. Examples
are methoxy, ethoxy and propoxy.
Examples
are formamido, acetamido and propionylamino. Examples of "Ci-4alkylS(O)a wherein a is 0 to 2" are methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of
are propionyl and acetyl. Examples of 'W-(d-4alkyl)amino" are methylamino and ethylamino. Examples of 'W,N-(C1-4alkyl)2amino" are di-N-methylamino, di-(7V-ethyl)amino and jV-ethyl-jV-methylamino. Examples of "C2-4alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-4alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of
'W-(Ci.4alkyl)sulphamoyl" are 7V-(methyl)sulphamoyl and 7V-(ethyl)sulphamoyl. Examples of "Λ/,Λ/-(Ci-4alkyl)2Sulphamoyl" are Λ/,Λ/-(dimethyl)sulphamoyl and Λ/-(methyl)-Λ/-(ethyl)sulphamoyl. Examples of
are methylaminocarbonyl and ethylaminocarbonyl. Examples
are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of 'W-(Ci-4alkoxy)carbamoyl" are methoxyaminocarbonyl and isopropoxyaminocarbonyl. Examples of 'W-(Ci-4alkyl)-Λ/-(Ci-4alkoxy)carbamoyl" are Λ/-methyl-7V-methoxyaminocarbonyl and N-methyl-TV-ethoxyaminocarbonyl. Examples of 'W-(Ci.4alkyl)ureido" are N'-methylureido and N'-isopropylureido. Examples of 'W,iV-(C1-4alkyl)2ureido" are NW-dimethylureido and N'-methyl-N'-isopropylureido. Examples of 'W-(Ci-4alkyl)hydrazinocarbonyl" are N'-methylhydrazinocarbonyl and
TV-isopropylhydrazinocarbonyl. Examples of W,N'-(Ci-4alkyl)2hydrazinocarbonyl" are ΛW-dimethylhydrazinocarbonyl and 7V'-methyl-7V -isopropylhydrazinocarbonyl. Examples of "Ci-4alkylsulphonylamino" are methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino. Examples of "Ci^alkylsulphonylaminocarbonyl" are methylsulphonylaminocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl. Examples
are methylsulphonyl, isopropylsulphonyl and t-butylsulphonyl. Examples of "Cs-όCycloalkyl" are cyclopropyl and cyclohexyl.
The term "formula (I)", unless otherwise specified, refers to all embodiments of formula (I), including but not limited to formula (IA) and formula (IB). Likewise, the term "formula (I')", unless otherwise specified, refers to all embodiments of formula (I'), including but not limited to formula (IA), formula (IB), and formula (IC). The phrase "compounds of the invention," unless otherwise specified, refers to all embodiments of formula (I) and (I'). A compound of formula (I) or (I') may form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.
Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, α-glycerophosphate, fumarate, hydrochloride, citrate, maleate, tartrate and hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, 7V-methylpiperidine, 7V-ethylpiperidine, procaine, dibenzylamine, 7V,7V-dibenzylethylamine, tris-(2-hydroxyethyl)amine, TV-methyl d-glucamine and amino acids such as lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. In one aspect of the invention the pharmaceutically-acceptable salt is the sodium salt.
However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be utilized whether pharmaceutically-acceptable or not.
Within the present invention it is to be understood that a compound of the formula (I) or (I') or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and / or topoisomerase IV and is not to be limited merely to any one tautomeric form
utilized within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names.
It will be appreciated by those skilled in the art that compounds of formula (I) or (I') may contain asymmetrically substituted carbon(s) and sulphur atom(s), and accordingly may exist in, and be isolated in, as far as those additional asymmetrically substituted carbon(s) and sulphur atom(s) are concerned, optically-active and racemic forms at those positions. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, at any additional asymmetrically substituted carbon(s) and sulphur atom(s), which possesses properties useful in the inhibition of DNA gyrase and / or topoisomerase IV.
Optically-active forms may be prepared by procedures known in the art for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase.
Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any polymorphic form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase and / or topoisomerase IV.
By way of clarity, compounds of the invention included all isotopes of the atoms present in formula (I) or (I') and any of the examples or embodiments disclosed herein. For example, H (or hydrogen) represents any isotopic form of hydrogen including 1H, 2H (D), and 3H (T); C represents any isotopic form of carbon including 12C, 13C, and 14C; O represents any isotopic form of oxygen including 16O, 17O and 18O; N represents any isotopic form of nitrogen including 13N, 14N and 15N; P represents any isotopic form of phosphorous including 31P and 32P; S represents any isotopic form of sulfur including 32S and 35S; F represents any isotopic form of fluorine including 19F and 18F; Cl represents any isotopic form of chlorine including 35Cl, 37Cl and 36Cl; and the like. In a preferred embodiment, compounds represented by formula (I) or (I') comprise isomers of the atoms therein in their naturally occurring abundance. However, in certain instances, it is desirable to enrich one or more atom in a particular isotope which would normally be present in less abundance. For example, 1H would normally be present in greater than 99.98% abundance; however, a
compound of the invention can be enriched in 2H or 3H at one or more positions where H is present. In one embodiment, when a compound of the invention is enriched in a radioactive isotope, for example 3H and 14C, they may be useful in drug and/or substrate tissue distribution assays. It is to be understood that the invention encompasses all such isotopic forms which inhibit DNA gyrase and / or topoisomerase IV.
It is also to be understood that certain compounds of the formula (I) or (I') and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit DNA gyrase and / or topoisomerase IV. There follow particular and suitable values for certain substituents and groups referred to in this specification. These values may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore, or hereinafter. For the avoidance of doubt each stated species represents a particular and independent aspect of this invention.
R1 is Ci-6alkyl. R1 is ethyl.
R2 is hydrogen. X1 is =N-. X1 is =C(R6)-.
X1 is =C(R6)-; wherein R6 is hydrogen. One of X2 and X3 is selected from (i) and the other is selected from (ii):
(i) -N= or -C(R7)=; (ii) -O-, -S-, -N(R8)- or -C(R9)(R10)-. X2 is selected from (i) and X3 is selected from (ii):
(i) -N= or -C(R7)=; (ii) -O-, -S-, -N(R8)- or -C(R9)(R10)-.
X2 is selected from (ii) and X3 is selected from (i): (i) -N= or -C(R7)=; (ϋ) -O-, -S-, -N(R8)- or -C(R9XR10)-. X2 is -N=. X2 is -C(R7)=.
X2 is -O-. X2 is -S-. X2 is -N(R8)-.
X2 is -C(R9XR10)-.
X3 is -N=.
X3 is -C(R7)=.
X3 is -O-.
X3 is -S-.
X3 is -N(R8)-.
X3 is -N(R8)-; wherein R8 is Ci-6alkyl;
X3 is -N(R8)-; wherein R8 is hydrogen or t-butoxycarbonyl. X3 is -C(R9XR10)-.
X2 is -N= and X3 is -NH-.
X2 is -N= and X3 is -N(CH3)-.
X2 is -N= and X3 is -N[C(O)OC(CH3)3]-.
X2 is -N= and X3 is -O-. X2 is -CH= and X3 is -S-.
X2 is -CH= and X3 is -N(CH3)-.
X1 and X2 are both =N-; X3 is -NR8-; and R8 is hydrogen or a Ci-6alkyl.
X1 is -C(R7)=; X2 is =N-; X3 is -NR8-; R7 is hydrogen; and R8 is hydrogen or a Ci- 6alkyl. X1 is -C(R7)=; X2 is =N-; X3 is -O-; and R7 is hydrogen.
X1 is =N-; X2 is =C(R7)-; X3 is -S-; and R7 is hydrogen.
Ring A is carbocyclyl.
Ring A is phenyl.
Ring A and (R4)n together are 4-cyanophenyl. Ring A and (R4)n together are 3-cyanophenyl.
Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R11.
Ring A is heterocyclyl.
Ring A is a pyridyl. Ring A is pyrid-3-yl.
Ring A is pyrid-4-yl.
Ring A is a thiazolyl.
Ring A is thiazol-2-yl.
Ring A and (R4)n together are 4-carboxy-thiazol-2-yl.
Ring A and (R4)n together are 4-carbamoyl-thiazol-2-yl.
Ring A and (R4)n together are 4-(7V-methyl-carbamoyl)-thiazol-2-yl.
Ring A and (R4)n together are 4-(ethoxycarbonyl)-thiazol-2-yl. Ring A is a triazolyl.
Ring A is l,2,4-triazol-3-yl.
R3 is hydrogen.
R is a heterocyclyl, wherein said heterocyclyl may be optionally substituted on carbon by one or more R14; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15.
R3 is a piperazinyl.
R3 is piperazin-1-yl.
R3 is a morpholinyl.
R3 is morpholin-4-yl. R3 is a piperidinyl.
R3 is piperidin-1-yl.
R3 is pyridyl.
R3 is pyrid-4-yl.
R3 is benzothiazolyl. R3 is benzothiazol-2-yl.
R3 is a phenyl which may be optionally substituted on one or more carbon with one or more independently selected R14.
R3 is phenyl.
R3 is 3-methyl-phenyl. R3 is 4-methyl-phenyl.
R3 is 2-fiuoro-phenyl.
R3 is hydrogen.
R3 is a heterocyclyl, wherein said heterocyclyl may be optionally substituted on carbon by one or more R14 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15.
R3 is a piperazinyl.
R3 is piperazin-1-yl.
R3 is a morpholinyl.
R3 is morpholin-4-yl.
R3 is a piperidinyl.
R3 is piperidin-1-yl.
R3 is pyridyl. R3 is pyrid-4-yl.
R3 is benzothiazolyl.
R3 is benzothiazol-2-yl.
R3 is a phenyl which may be optionally substituted on one or more carbon with one or more independently selected R14 . R3' is phenyl.
R3 is 3-methyl-phenyl.
R3 is 4-methyl-phenyl.
R3 is 2-fluoro-phenyl.
R3 is 4-(moropholinomethyl)-phenyl. R4 is cyano.
R4 is carboxy.
R4 is carbamoyl.
R4 is N-methyl-carbamoyl.
R4 is N-ethyl-carbamoyl. R4 is ethoxycarbonyl. n is 0. n is 1.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein: R1 is Ci-6alkyl;
R2 is hydrogen;
X1 is =C(R6)-; wherein R6 is hydrogen;
X2 is -N=;
X3 is -N(R8)-; wherein R8 is hydrogen or Ci_6alkoxycarbonyl; Ring A is pyridyl;
R3 is hydrogen; n is 0; or a pharmaceutically acceptable salt thereof.
According to a further feature of the invention, there is provided a compound of formula (I) which is a compound of formula (IA):
(IA) wherein R1, R2, X1, R3, R8, Ring A, R4 and n are as described herein above; or a pharmaceutically acceptable salt thereof. In one embodiment of formula (IA), R3 is H. In another embodiment, ring A is pyridyl. In another embodiment of formula (IA), R3 is H and ring A and (R4)n together are pyrid-3-yl. In another embodiment of formula (IA), R3 is piperazinyl and ring A together with (R4)n is 4-carboxy-thiazole-2-yl, 4-carbamoyl-thiazol-2- yl or 4-ethoxycarbonyl-thiazol-2-yl. In another embodiment of formula (IA), R3 is morpholino and ring A together with (R4)n is 4-carboxy-thiazole-2-yl, 4-(N-methyl- carbamoyl)-thiazol-2-yl, or 4-ethoxycarbonyl-thiazol-2-yl. In another embodiment of formula (IA), R8 is H or methyl. In another embodiment of formula (IA), R3 is piperdinyl and ring A together with (R4)n is l,2,4-triazol-3-yl, 4-carboxy-thiazole-2-yl, 4-(N-methyl-carbamoyl)- thiazol-2-yl, or 4-carbamoyl-thiazol-2-yl. In another embodiment of formula (IA), R3 is phenyl, 3-methylphenyl, 4-methylphenyl, or 2-fluorophenyl and ring A together with (R4)n is l,2,4-triazol-3-yl, 4-carboxy-thiazole-2-yl, 4-(N-methyl-carbamoyl)-thiazol-2-yl, or 4- ethoxycarbonyl-thiazol-2-yl.
According to a further feature of the invention, there is provided a compound of formula (I) which is a compound of formula (IB):
(IB)
R1, R2, X1, R3, Ring A, R4 and n are as described herein above; or a pharmaceutically acceptable salt thereof. In one embodiment of formula (IB), R3 is H, and ring A together with (R4)n is pyrid-3yl, pyrid-4-yl, 3-cyano-phenyl, or 4-cyanophenyl.
According to a further feature of the invention, there is provided a compound of formula (I') which is a compound of formula (IC):
(IC) R1, R2, X1, R3 , Ring A, R4 and n are as described herein above; or a pharmaceutically acceptable salt thereof. In one embodiment of formula (IC), R3 is pyrid-4-yl and ring A together with (R4)n is 4-carboxy-thiazole-2-yl or 4-ethoxycarbonyl-thiazol-2-yl. In another embodiment of formula (IC), R3' is benzothiazol-2-yl and ring A together with (R4)n is 4- carboxy-thiazole-2-yl, 4-(N-methyl-carbamoyl)-thiazol-2-yl, or 4-ethoxycarbonyl-thiazol-2- yl. In another embodiment of formula (IC), R3' is 4-(morpholinomethyl)-phenyl, and ring A together with (R4)n is 4-carboxy-thiazole-2-yl or 4-ethoxycarbonyl-thiazol-2-yl. In another embodiment of formula (IC), R3' is phenyl and ring A together with (R4)n is 4- ethoxycarbonyl-thiazol-2-yl.
Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention. In further aspects, the present invention also comprises any two or more compounds of the Examples.
In one embodiment of the invention are provided compounds of formula (I) or (I'). In an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I) or (I').
In a further aspect the present invention provides a process for preparing a compound of formula (I) or (I') or a pharmaceutically-acceptable salt thereof.
Thus, the present invention also provides that the compounds of the formula (I) or (I') and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated): Process a) reacting an amine of formula (II):
(HI) (in') or an activated derivative thereof;
Process b) reacting an acid of formula (IV):
(IV) or an activated derivative thereof; with an amine of formula (V) or (V'):
(V) (V')
Process c) for compounds of formula (I) or (I') wherein R2 is hydrogen; reacting an isocyanate of formula (VI): i ^O
R.
(VI) with an amine of formula (V) or (V');
Process d) reacting an isocyanate of formula (VII) or (VII'):
(VII) (VIP) with an amine of formula (II);
Process e) for compounds of formula (I) or (I') wherein the five membered ring of formula (I) or (I') is attached to a double bond of Ring A; reacting a compound of formula (VIII) or (VIII'):
(IX) wherein one of Xa and Xb is a displaceable group "L" and the other is an organometallic reagent "M";
Process f) for compounds of formula (I) or (I') wherein Ring A is a thiazole-2-yl; reacting a compound of formula (X) or (X'):
(X) (X') with a compound of formula (XI):
Process g) for compounds of formula (I) or (I') wherein Ring A is a l,2,4-triazol-3-yl; reacting a compound of formula (XII) or (XII'):
(XII) (XII') with hydrazine hydrate and a compound of formula (XIII):
(XIII)
Process h) for compounds of formula (I) or (I') wherein R3 or R3 has a double bond that is attached directly to the six membered fused ring system; reacting a compound of formula (I) or (Y) wherein R3 or R3', respectively, is hydrogen with a compound of formula (XIV) or (XIV):
. R25 R25
O O
/-R26
R3'' O
(XIV) (XIV) wherein R25 and R26 are hydrogen or a C^aUcyl; or R25 and R26 together with -0-B-O- form a five or six membered ring; and thereafter if necessary: i) converting a compound of the formula (I) or (I') into another compound of the formula (I) or (F); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
L is a displaceable group. Suitable values for L include chloro, bromo, tosyl and trifluoromethylsulphonyloxy.
M is an organometallic reagent, suitable values for M include organoboron and organotin reagents, in particular B(ORZ)2 where Rz is hydrogen or C^aUcyl for example B(OH)2; and Sn(Ry)3 where Ry is Ci-6alkyl for example Sn(Bu)3.
Specific reaction conditions for the above reactions are as follows. Process a) and Process b): Amines and acids may be coupled together in the presence of a
suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole (CDI) and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-α/Ay/-pyridines such as 2,6-lutidine or
2,6-di-fe/t-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40 0C.
Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40 0C. Compounds of formula (III) may be prepared according to the following scheme:
CDI (V) (III)
Scheme 1 Compounds of formula (III') may be prepared in a likewise manner.
Compounds of formula (V) may be prepared according to the following scheme:
Scheme 2
Wherein L' is CN, CHO, CO2H or COCl. Compounds of formula (V) can be prepared in a likewise manner.
Compounds of formula (II), (IV), (Va) and (Vb) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.
Process c) and Process d): Isocyanates and amines may be coupled together in a suitable solvent such as chloroform, dicholormethane, toluene, or 7V-methylpyrrolidine in the presence of base such as triethylamine and with the addition of heat.
Compounds of formula (VII) may be prepared according to the following scheme: formic acid (V) " (VII) heat
Scheme 3 Compounds of formula (VII') may be prepared in a likewise manner.
Compounds of formula (VI) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art. Process e) Compounds of formula (VIII) and (IX) may be reacted together by coupling chemistry utilizing an appropriate catalyst. Such reactions are well known in the art. For example, where M is an organoboron group, Pd(PPh3 )4 and a suitable base such as sodium carbonate can be utilized. In the case where M is an organotin reagent, Pd(PPh3 )4 can be utilized as the catalyst. The reactions take place in suitable solvents and may require thermal conditions.
Compounds of formula (VIII) may be prepared according to the following scheme:
Scheme 4 wherein Y is halo. Compounds of formula (VIIF) may be prepared in a likewise manner. Compounds of formula (Villa), (VIIIb) and (IX) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.
Process β: Formation of a thiazole-2-yl ring A can be carried out by heating a compound of formula (X) or formula (X') with a compound of formula (XI) in a suitable polar solvent such as an alcohol.
Compounds of formula (X) or (X') can be prepared by reacting a compound of formula (XI) or (XI'), respectively, with ammonium sulphide in a suitable polar solvent such as an alcohol, typically, with the addition of heat.
Compounds of formula (XI) or (XI') wherein R3 or R3 is an amine, such as -NH2, N- alkyl amine, N,N-dialkylamine or a non-aromatic heterocycle comprising at least one secondary nitrogen ring member can be prepared by heating a compound of formula (XIa) with an amine derivative represented by formula (XIb)
(XIa) (XIb) (Xl)
Scheme V
Wherein R and R are each independently hydrogen, a Ci_6alkyl, or R and R together with the nitrogen to which they are attached form a heterocycle.
Compounds of formula (XI) or (XI') wherein R3 or R3 is an aromatic carbocycle or heterocycle or a group which has a double bond linked the six membered fused ring system can be prepared by coupling a compound of formula (XIa) with a compound of formula (XIV) or (XIV) via a reaction analogous to that described in Process g).
A compound of formula (XIa) can be prepared by reacting 2-amino-6-chloro-9- methyl-9H-purine-8-carbonitrile (see J Chem Soc, Perkin Trans I, 1977, 1003 for preparation) with an isocyanate derivative in a manner analogous to that described for Process c).
Process g): Formation of a l,2,4-triazol-3-yl ring A can be carried out by heating a compound of formula (XI) or formula (XF) in the presence of hydrazine and a compound of formula (XIII). When the compound of formula (XIII) is formic acid it may be used as the solvent for the reaction.
Process h): Compounds of formula (I) or (I') in which R3 or R3 is hydrogen may be reacted with a compound of formula (XIV) or (XIV) by coupling chemistry utilizing an appropriate catalyst. Such reactions are well known in the art. For example, Pd(PPh3 )4 and a suitable base such as sodium carbonate can be utilized. The reactions take place in suitable solvents and may require thermal conditions.
The formation of a pharmaceutically-acceptable salt is within the skill of an ordinary organic chemist using standard techniques.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or
generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. The reagents used to introduce such ring substituents are either commercially available or are made by processes known in the art. Introduction of substituents into a ring may convert one compound of the formula (I) or (I') into another compound of the formula (I) or (I'). Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents, oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings. The reagents and reaction conditions for such procedures are well known in the chemical art.
Particular examples of aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group. Examples of modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl. The skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products. If not commercially available, the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples. It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature. The reader is further referred to Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in compounds. The instances where protection is necessary or desirable are known to those skilled in the art, as are suitable methods for such protection. Conventional protecting groups may be used in accordance with standard practice (for illustration see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991).
Examples of a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.
A suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or for example, an allyl group which may be removed, for example, by use of a palladium catalyst such as palladium acetate.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.
Optically active forms of a compound of the invention may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates. Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure. Enzyme Potency Testing Methods Compounds may be tested for inhibition of GyrB ATPase activity using an ammonium molybdate/malachite green-based phosphate detection assay (Lanzetta, P. A., L. J. Alvarez, P. S. Reinach, and O. A. Candia, 1979, 100: 95-97). Assays can be performed in multiwell plates in 100 μl reactions containing: 50 mM HEPES buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1 ,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 5 μg/ml sheared salmon sperm DNA, 2.5 nM E. coli GyrA, 2.5 nM E. coli GyrB, 250 μM ATP, and compound in dimethylsulfoxide. Reactions can be quenched with 150 μl of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium mo lybdate tetrahydrate, and 1 M hydrochloric acid. Plates can be read in an absorbance plate reader at 650 nm and percent inhibition values may be calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 μM) reactions as 100% inhibition controls. Compound potency can be based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations. Inhibition of E. coli GyrA and/or GyrB can be assessed by observing percent inhibition at a given compound concentration.
Compounds may be tested for inhibition of topoisomerase IV ATPase activity as described above for GyrB except the lOOμl reactions may contain the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM
1,4-dithio-DL-threitol, 0.005% Brij-35, 5 μg/ml sheared salmon sperm DNA, 2.5 nM Streptococcus pneumoniae ParE, 160 μM ATP, and compound in dimethylsulfoxide. Compound potency may be based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations. Compound activity against S. pneumoniae can be assessed by observing percent inhibition at a given compound concentration. Inhibition of S. pneumoniae ParE can be assessed by observing percent inhibition at a given compound concentration.
Compounds may be tested for inhibition of topoisomerase IV ATPase activity as described above for GyrB except the 30μl reactions contained the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM 1,4- Dithio-DL-threitol, 0.005% Brij-35, 5 μg/ml sheared salmon sperm DNA, 1.25 nM S. pneumoniae ParE, 160 μM ATP, and compound in dimethylsulfoxide. Compound potency may be based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations. Inhibition of S. pneumoniae ParE can be assessed by observing percent inhibition at a given compound concentration. Compounds in the following table were tested in an assay substantially similar to the assay described in this paragraph to determine percent inhibition of S. pneumoniae ParE at a compound concentration of 50 μM:
In general, compounds of the invention have IC50 values of <200μM in one or both assays described herein above. For example, Example 1 showed an IC50 of 20.2 μM against Streptococcus pneumoniae ParE. However, the compounds in Table A have IC50 values of >200 μM against Streptococcus pneumoniae ParE.
Bacterial Susceptibility Testing Methods
Compounds may be tested for antimicrobial activity by susceptibility testing in liquid media. Compounds may be dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays. The organisms used in the assay may be grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the
organism. The suspension can be a 0.5 McFarland and a further 1 in 10 dilution can be made into the same liquid medium to prepare the final organism suspension in 100 μL. Plates can be incubated under appropriate conditions at 37 0C for 24 hrs prior to reading. The Minimum Inhibitory Concentration (MIC) may be determined as the lowest drug concentration able to reduce growth by 80% or more.
According to a further feature of the invention there is provided a compound of the formula (I) or (I'), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.
We have found that compounds of the present invention inhibit bacterial DNA gyrase and / or topoisomerase IV and are therefore of interest for their antibacterial effects. In one aspect of the invention, the compounds of the invention inhibit bacterial DNA gyrase and are therefore of interest for their antibacterial effects. In one aspect of the invention, the compounds of the invention inhibit topoisomerase IV and are therefore of interest for their antibacterial effects. In one aspect of the invention, the compounds of the invention inhibit both DNA gyrase and topoisomerase IV and are therefore of interest for their antibacterial effects.
It is expected that the compounds of the present invention will be useful in treating bacterial infections. In one aspect of the invention "infection" or "bacterial infection" refers to a gynecological infection. In one aspect of the invention "infection" or "bacterial infection" refers to a respiratory tract infection (RTI). In one aspect of the invention "infection" or "bacterial infection" refers to a sexually transmitted disease. In one aspect of the invention "infection" or "bacterial infection" refers to a urinary tract infection. In one aspect of the invention "infection" or "bacterial infection" refers to acute exacerbation of chronic bronchitis (ACEB). In one aspect of the invention "infection" or "bacterial infection" refers to acute otitis media. In one aspect of the invention "infection" or "bacterial infection" refers to acute sinusitis. In one aspect of the invention "infection" or "bacterial infection" refers to an infection caused by drug resistant bacteria. In one aspect of the invention "infection" or "bacterial infection" refers to catheter-related sepsis. In one aspect of the invention "infection" or "bacterial infection" refers to chancroid. In one aspect of the invention "infection" or "bacterial infection" refers to chlamydia. In one aspect of the invention
"infection" or "bacterial infection" refers to community-acquired pneumonia (CAP). In one aspect of the invention "infection" or "bacterial infection" refers to complicated skin and skin structure infection. In one aspect of the invention "infection" or "bacterial infection" refers to
uncomplicated skin and skin structure infection. In one aspect of the invention "infection" or "bacterial infection" refers to endocarditis. In one aspect of the invention "infection" or "bacterial infection" refers to febrile neutropenia. In one aspect of the invention "infection" or "bacterial infection" refers to gonococcal cervicitis. In one aspect of the invention "infection" or "bacterial infection" refers to gonococcal urethritis. In one aspect of the invention "infection" or "bacterial infection" refers to hospital-acquired pneumonia (HAP). In one aspect of the invention "infection" or "bacterial infection" refers to osteomyelitis. In one aspect of the invention "infection" or "bacterial infection" refers to sepsis. In one aspect of the invention "infection" or "bacterial infection" refers to syphilis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Acinetobacter baumanii. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Acinetobacter haemolyticus . In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Acinetobacter junii. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Acinetobacter johnsonii. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Acinetobacter Iwoffi. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by B acteroides bivius. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by B acteroides fragilis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Burkholderia cepacia. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Campylobacter jejuni. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Chlamydia pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Chlamydia urealyticus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Chlamydophila pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Clostridium difficili. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Enterobacter aerogenes. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Enterobacter cloacae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Enterococcus faecalis . In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Enterococcus faecium. In one aspect of the invention an "infection" or "bacterial infection"
refers to an infection caused by Escherichia coli. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Gardnerella vaginalis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Haemophilus par ainfiuenzae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Haemophilus influenzae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Helicobacter pylori. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Klebsiella pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Legionella pneumophila. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by
Methicillin-resistant Staphylococcus aureus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Methicillin-susceptible Staphylococcus aureus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Moraxella catarrhalis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Morganella morganii. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Mycoplasma pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by N ' eisseria gonorrhoeae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Penicillin- resistant Streptococcus pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Penicillin-susceptible Streptococcus pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus magnus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus micros. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by
Peptostreptococcus anaerobius . In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus asaccharolyticus . In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus prevotii. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus tetradius. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus vaginalis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Proteus mirabilis. In one aspect of the invention an
"infection" or "bacterial infection" refers to an infection caused by Pseudomonas aeruginosa. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Quinolone-Resistant Staphylococcus aureus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Quinolone-Resistant Staphylococcus epidermis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Salmonella typhi. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Salmonella paratyphi. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Salmonella enteritidis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Salmonella typhimurium. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Serratia marcescens. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Staphylococcus aureus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Staphylococcus epidermidis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by
Staphylococcus saprophyticus . In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Streptococcus agalactiae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Streptococcus pneumoniae. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Streptococcus pyogenes. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Stenotrophomonas maltophilia. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Ureaplasma urealyticum. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Vancomycin-Resistant Enter ococcus faecium. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by
Vancomycin-Resistant Enterococcus faecalis . In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Vancomycin-Resistant Staphylococcus aureus. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Vancomycin-Resistant Staphylococcus epidermis. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Acinetobacter spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Bacteroides spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Burkholderia
spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Campylobacter spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Chlamydia spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Chlamydophila spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Clostridium spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Enterobacter spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Enterococcus spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Escherichia spp.. In one aspect of the invention an "infection" or
"bacterial infection" refers to an infection caused by Gardnerella spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Haemophilus spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Helicobacter spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Klebsiella spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Legionella spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Moraxella spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Morganella spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Mycoplasma spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Neisseria spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Peptostreptococcus spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Proteus spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Pseudomonas spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Salmonella spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Serratia spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Staphylococcus spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Strep toccocus spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by Stenotrophomonas spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused
by Ureaplasma spp.. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by aerobes. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by obligate anaerobes. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by facultative anaerobes. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by gram-positive bacteria. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by gram-negative bacteria. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by gram- variable bacteria. In one aspect of the invention an "infection" or "bacterial infection" refers to an infection caused by atypical respiratory pathogens.
According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof. According to a further feature of the invention there is provided a method for inhibition of bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof as defined hereinbefore. According to a further feature of the invention there is provided a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof as defined hereinbefore.
According to a further feature of the invention there is provided a method of treating a bacterial infection selected from a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and /or syphilis in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to
said animal an effective amount of a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof as defined hereinbefore.
A further feature of the present invention is a compound of formula (I) or (I') and pharmaceutically acceptable salts thereof for use as a medicament. Suitably the medicament is an antibacterial agent.
According to a further aspect of the invention there is provided the use of a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the production of an anti-bacterial effect in a warm-blooded animal such as a human being. According to a further aspect of the invention there is provided the use of a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the inhibition of bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided the use of a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a bacterial infection in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided the use of a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a bacterial infection selected from a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and / or syphilis in a warm-blooded animal such as a human being.
According to a further aspect of the invention there is provided a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.
According to a further aspect of the invention there is provided a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof for use in inhibition of
bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided a compound of formula (I) or (I'), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection selected from a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and / or syphilis in a warm-blooded animal such as a human being.
In order to use a compound of the formula (I) or (I') or a pharmaceutically-acceptable salt thereof, for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or (I') or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in a warm-blooded animal, such as a human being.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and / or topoisomerase IV in a warm-blooded animal, such as a human being.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in a warm-blooded animal, such as a human being.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I) or (I') as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a gynecological infection, a respiratory tract infection (RTI), a sexually transmitted disease, a urinary tract infection, acute exacerbation of chronic bronchitis (ACEB), acute otitis media , acute sinusitis, an infection caused by drug resistant bacteria, catheter-related sepsis, chancroid, chlamydia, community-acquired pneumonia (CAP), complicated skin and skin structure infection, uncomplicated skin and skin structure infection, endocarditis, febrile neutropenia, gonococcal cervicitis, gonococcal urethritis, hospital-acquired pneumonia (HAP), osteomyelitis, sepsis and/or syphilis in a warm-blooded animal, such as a human being.
The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing). The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as
ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art. Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame). Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting
agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present. The pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.
Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent. The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.
Compositions for administration by inhalation may be in the form of a conventional pressurized aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.
For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from
about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. In one aspect of the invention a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
As noted above, one embodiment of the present invention is directed to treating or preventing diseases caused by bacterial infections, wherein the bacteria comprise a GyrB ATPase or topoisomerase IV ATPase enzyme. "Treating a subject with a disease caused by a bacterial infection" includes achieving, partially or substantially, one or more of the following: the reducing or amelioration of the progression, severity and/or duration of the infection, arresting the spread of an infection, ameliorating or improving a clinical symptom or indicator associated with a the infection (such as tissue or serum components), and preventing the reoccurrence of the infection.
As used herein, the terms "preventing a bacterial infection" refer to the reduction in the risk of acquiring the infection, or the reduction or inhibition of the recurrence of the infection. In a preferred embodiment, a compound of the invention is administered as a preventative measure to a patient, preferably a human, before a surgical procedure is preformed on the patient to prevent infection.
As used herein, the term "effective amount" refers to an amount of a compound of this invention for treating or preventing a bacterial infection is an amount which is sufficient to prevent the onset of an infection, reduce or ameliorate the severity, duration, or progression, of an infection, prevent the advancement of an infection, cause the regression of an infection, prevent the recurrence, development, onset or progression of a symptom associated with an infection, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
In addition to its use in therapeutic medicine, compounds of formula (I) or (I') and their pharmaceutically acceptable salts are also useful as pharmacological tools in the
development and standardisation of in- vitro and in- vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase and / or topoisomerase IV in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and particular embodiments of the compounds of the invention described herein also apply.
Combinations
The compounds of the invention described herein may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination. Suitable classes and substances may be selected from one or more of the following: i) other antibacterial agents for example macrolides e.g. erythromycin, azithromycin or clarithromycin; quinolones e.g. ciprofloxacin or levofloxacin; β-lactams e.g. penicillins e.g. amoxicillin or piperacillin; cephalosporins e.g. ceftriaxone or ceftazidime; carbapenems, e.g. meropenem or imipenem etc; aminoglycosides e.g. gentamicin or tobramycin; or oxazolidinones; and/or ii) anti-infective agents for example, an antifungal triazole e.g. or amphotericin; and/or iii) biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products; and/or iv) efflux pump inhibitors.
Therefore, in a further aspect of the invention there is provided a compound of the formula (I) or (I'), or a pharmaceutically acceptable salt thereof and a chemotherapeutic agent selected from: i) one or more additional antibacterial agents; and/or ii) one or more anti-infective agents; and/or iii) biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products; and/or iv) one or more efflux pump inhibitors.
Examples
The invention is now illustrated but not limited by the following Examples in which
unless otherwise stated :-
(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
(ii) operations were generally carried out at ambient temperature, that is typically in the range 18-26 0C and without exclusion of air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;
(iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated; (iv) yields are given for illustration only and are not necessarily the maximum attainable; (v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques; proton magnetic resonance spectra is quoted and was generally determined in DMSOd6 unless otherwise stated using a Bruker DRX-300 spectrometer operating at a field strength of 300 MHz. Chemical shifts are reported in parts per million downfield from tetramethysilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad;
(vi) fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected or using Agilent 1 lOOseries LC/MSD equipped with Sedex 75ELSD, run in atmospheric pressure chemical ionization mode and, where appropriate, either positive ion data or negative ion data were collected; mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe; where indicated ionization was effected by electron impact (EI), fast atom bombardment (FAB) or electrospray (ES); values for m/z are given; generally, only ions which indicate the parent mass are reported;
(vii) each intermediate was generally purified to the standard required for the subsequent stage and was characterized in sufficient detail to confirm that the assigned structure was correct; purity was assessed by high pressure liquid chromatography, thin layer chromatography, or NMR and identity was determined by infra-red spectroscopy (IR), mass spectroscopy or NMR spectroscopy as appropriate; (vii) the following abbreviations may be used: DMSO is dimethylsulfoxide; CDCI3 is deuterated chloroform;
MS is mass spectroscopy; EtOAc is ethyl acetate;
EDC is N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; HATU is 2-(lH-7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyl uronium hexafluorophosphate methanaminium; OAc is acetate; THF is tetrahydrofuran; MeOH is methanol; and TFA is trifluoroacetic acid; Xantphos is 4,5-bis(diphenylphosphino)-9,9-dimethyl-xanthene; and
(viii) temperatures are quoted as 0C.
Example 1
A/-Ethyl-A/*-(2-pyridin-3-yl-3H-imidazor4,5-olpyridin-5-vl)urea
tert-Butyl 5-(3-ethylureido)-2-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine-3-carboxylate (Example 2; 4.5 mg, 0.01 mmol) was dissolved in a CH2Cl2 (9 mL). TFA (1 mL, 0.01 mmol) was added in a single portion and the reaction was stirred at room temperature overnight, and was monitored by LC/MS. The solvent was removed and the residue was suspended in 4N HCl in dioxane. The solids were stirred for 2 hours, filtered and dried in vacuo. Isolation gave 2.4 mg of the title compound (hydrochloride salt) in 64% yield. LC/MS (ES+) [(M+H)+]: 283
Example 2 ferf-Butyl 5-(3-ethylureido)-2-(pyridin-3-yl)-3H-imidazor4,5-blpyridine-3-carboxylate
In a 1-neck glass round bottom flask purged with nitrogen, Pd(OAc)2 (48.9 mg, 0.07 mmol), and Xantphos (84 mg, 0.15 mmol) were combined and dissolved in dioxane (3 mL). The solution was degassed. tert-Butyl 5-chloro-2-pyridin-3-yl-3H-imidazo[4,5-ό]pyridine-3- carboxylate (Intermediate 3, 200 mg, 0.60 mmol), 1-ethylurea (53.3 mg, 0.60 mmol), potassium tert-butoxide (102 mg, 0.91 mmol) and water (16.33 mg, 0.91 mmol) were added successively to the flask. The reaction mixture was then heated to 1000C and monitored by LC/MS. Analysis showed product and the de-protected starting material. The Boc-group is very unstable and falls off during the reaction. Consequently the reaction stops with about 30% product formed. The reaction was dilute with EtOAc and wash with water, then the organic layer was dried over Na2SO4, filter and concentrate. The concentrate was dissolved in DMSO and purify by Gilson HPLC. Isolation gave 4.5 mg of the title compound in 2% yield. LC/MS (ES+)[(M+H)+]: 383 for Ci9H22N6O3.
Example 3
To argon purged dioxane (50 mL) was added palladium acetate (40 mg, 0.2 mmol) and Xantphos (140 mg, 0.25 mmol) under nitrogen atmosphere and stirred for 1 h at room temperature. 5-Chloro-2-pyridin-3-yl-oxazolo[5,4-b]pyridine (Intermediate 11, 0.85 mmol) was added, followed by N-ethyl urea (0.18g, 2 mmol), potassium tert-butoxide (140 mg, 1.3 mmol), and nitrogen purged water (0.02g, 1.3 mmol). The reaction mixture was then refluxed at 100 0C for 14 h, then cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (3x10 mL). The combine extracts were washed with water (20 mL) and brine, then dried over anhydrous sodium sulphate and concentrated to a residue. The residue was subjected to column chromatography (silica, chloroform-methanol) to yield the title compound.
MS (ES): 284 (M+ 1) for Ci4H13N5O2 400 MHz, CDCl3: δ 1.41 (t, J= 7.2 Hz, 3H), 3.49-3.54 (m, 2H), 6.96 (d, J = 8.5 Hz, IH), 7.50 (dd, J= 4.8, 7.9 Hz, IH), 8.01 (d, J= 8.5 Hz, IH), 8.49 (d, J= 8.0 Hz, IH), 8.74(br s, IH), 8.79 (d, J= 4.2 Hz, IH), 8.88 (s, IH), 9.46 (s, IH)
Examples 4-6
The following Examples were prepared by the procedure described in Example 3 from the starting materials (SM) indicated.
Example 7
2-r2-(3-Ethyl-ureido)-9-methyl-6-piperazin- 1 -yl-QH-purin-δ-yll-thiazole^-carboxylic acid ethyl ester
To a stirred solution of 4-[2-(3-ethyl-ureido)-9-methyl-8-thiocarbamoyl-9H-purin-6-yl]- piperazine-1-carboxylic acid tert-butyl ester (Intermediate 16, 1.83 g, 3.95 mmol) in ethanol (20 mL), ethyl 3-bromo-2-oxopropanoate (0.774 mL, 5.92 mmol) was added and the mixture was heated to 100 0C for 18 h. The reaction mixture was cooled to room temperature and the resulting residue was washed with acetonitrile followed by diethylether. The solid that formed was collected by filtration and dried to afford 1.65 g (89%) of 2-[2-(3-ethyl-ureido)-9-methyl- 6-piperazin-l-yl-9H-purin-8-yl]-thiazole-4-carboxylic acid ethyl ester.
1H NMR (400 MHz. DMSO-dfi): δ 1.17 (t, 3H), 1.36 (t, 3H), 3.26-3.50 (m, 8H), 4.116 (s, 3H), 4.336-4.389 (q, 4H), 8.69 (s, IH), 8.88 (t, IH), 9.265 (br s, IH).
Example 8 2-r2-(3-Ethyl-ureido)-9-methyl-6-piperazin- 1 -yl-9H-purin-8-yll-thiazole-4-carboxylic acid
To a stirred solution of 2-[2-(3-ethyl-ureido)-9-methyl-6-piperazin-l-yl-9H-purin-8-yl]- thiazole-4-carboxylic acid ethyl ester (Example 7, 0.75 g, 1.63 mmol) in methanol (10 mL), 2 M sodium hydroxide (10 mL) was added, and the mixture was stirred at room temperature for 5 h. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissovled in water and acidified to pH = 2 with 2N hydrochloric acid solution (10 mL). The solid obtained was filtered and then co-distilled with toluene (2 x 20 mL) to afford 0.65 g (92.3%) of 2-[2-(3-ethyl-ureido)-9-methyl-6-piperazin- 1 -yl-9H-purin-8-yl]-thiazole-4- carboxylic acid.
1H NMR (400 MHz. DMSO-cϋ: δ 1.17 (t, 3H), 3.28-3.33 (m, 6H), 3.49 (q, 2H), 4.11 (s, 3H), 4.45 (br s, 2H), 8.62 (s, IH), 8.9 (t, IH), 9.26 (br s, IH), 9.7 (br s, IH).
Example 9
2-r2-(3-Ethyl-ureido)-9-methyl-6-piperazin- 1 -yl-gH-purin-δ-yll-thiazole^-carboxylic acid amide
In a sealed tube (20 mL), 2-[2-(3-Ethyl-ureido)-9-methyl-6-piperazin-l-yl-9H-purin-8-yl]- thiazole-4-carboxylic acid ethyl ester (Example 7, 0.3 g, 0.653 mmol) was taken and 30% of aqueous ammonia (15 mL) was added. The reaction mixture was heated to 100 0C for 18 h, then cooled to room temperature. The solid that formed was collected by filtration and washed with acetonitrile (5 mL) and diethylether (5 mL), then dried under vacuum to afford 0.12 g (42.7%) of 2-[2-(3-ethyl-ureido)-9-methyl-6-piperazin-l-yl-9H-purin-8-yl]-thiazole-4- carboxylic acid amide. 1H NMR (400 MHz. DMSO-dfi): δ 1.17 (t, 3H), 3.72 (t, 4H), 3.26 (q, 2H), 4.11 (s, 3H), 4.20 (br s, 4H), 7.74 (s, IH), 7.90 (s, IH), 8.36 (s, IH), 9.03 (t, IH), 9.08 (s, IH).
Example 10
2-r2-(3-Ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8-yll-thiazole-4-carboxylic acid ethyl ester
To a stirred solution of 2-(3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purine-8- carbothioic acid amide (Intermediate 18, 1.4 g, 3.85 mmol) in ethanol (20 mL) was added ethyl 3-bromo-2-oxopropanoate (0.725 mL, 5.78 mmol). The reaction mixture was heated to 100 0C for 15 h. After completion of the reaction, the reaction mixture was concentrated to
dryness, and the residue was taken up in water (10 mL) and stirred for 20 min. The solid obtained was filtered and washed with diethyl ether and finally co-distilled with toluene (2 x 25 mL) to afford 1.6 g, (96%) of 2-[2-(3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin- 8-yl]-thiazole-4-carboxylic acid ethyl ester as pale-yellow solid. 1H NMR (400 MHz. CDCl1): δ 1.16 (t, 3H), δ 1.34 (t, 3H), δ 3.26 (q, 2H), δ 3.76 (t, 4H), δ 4.09 (s, 3H), δ 4.21 (bs, 4H), δ 4.35 (q, 2H), δ 8.65 (s, IH), δ 8.95 (bs, IH), δ 9.21 (bs, IH). Mass (APCI. +ve scan): m/z 461 (M+H) for Ci9H24N8O4S.
Example 11 2-r2-(3-Ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8-yll-thiazole-4-carboxylic acid
To a stirred solution of 2-[2-(3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]- thiazole-4-carboxylic acid ethyl ester (Example 10, 0.25 g, 0.541 mmol) in methanol (15 mL) was added 2 N sodium hydroxide solution (6 mL), and the mixture was stirred at room temperature for 4 h. After completion of the reaction, the reaction mixture was concentrated to dryness. The residue was taken up in water (10 mL) and was extracted with ethyl acetate (2 x 20 mL). The aqueous layer was acidified to pH 2, and the solid precipitate formed. The solid was filtered and washed with diethyl ether and finally co-distilled with toluene (2 x 20 mL) to afford 1.2 g, (51%) of 2-[2-(3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8- yl]-thiazole-4-carboxylic acid as pale brown solid.
1H NMR (400 MHz. DMSO-dfi): δ 1.16 (t, 3H), δ 3.28 (q, 2H), δ 3.77 (t, 3H), δ 4.09 (s, 3H), δ 4.21 (bs, 4H), δ 8.58 (s, IH), δ 9.01 (bs, IH), δ 9.25 (bs, IH). Mass (APCI. +ve scan): m/z 433 (M+H) for. Ci7H20N8O4S.
Example 12
2-r2-(3-Ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8-yll-thiazole-4-carboxylic acid methyl amide
To a stirred solution of 2-[2-(3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]- thiazole-4-carboxylic acid (Example 11, 0.2 g, 0.464 mmol) in dry dimethyl formamide (5 mL) was added N-methyl morpholine (0.153 mL, 1.392 mmol), and the mixture was cooled to 0 0C. HOBt (0.142 g, 0.928 mmol) was added to the reaction mixture, followed by methyl amine (2 M solution in THF) (0.225 mL, 0.464 mmol), and the mixture was stirred for 10 min. EDCHCl (0.177 g, 0.928 mmol) was added, and the mixture was stirred overnight at room temperature. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (4 x 20 mL). The organic layer was washed with 2N hydrochloric acid (1 x 30 mL), followed by a bicarbonate wash (1 x 30 mL). The organic layer was then dried over anhydrous sodium sulfate, then concentrated to give a yellow solid which was triturated with acetonitrile and filtered to afford 0.06 g, (29.1%) of 2- [2-(3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purin-8-yl]-thiazole-4-carboxylic acid methyl amide as yellow solid.
Example 13 l-Ethyl-3-r9-methyl-6-(piperidin-l-vπ-8-(4H-1.2.4-triazol-3-vπ-9H-purin-2-yl1urea
H H \ H
Hydrazine hydrate (61 mg, 1.22 mM) was added to a stirred solution of l-[8-cyano-9-methyl- 6-(piperidin-l-yl)-9H-purin-2-yl]-3-ethylurea (Intermediate 20, 200 mg, 0.609 mmol) in formic acid (5 mL). The mixture was heated to reflux for 24 h, then cooled to room temperature and concentrated under reduced pressure. Isopropyl alcohol (5 mL) was added to the resulting residue, and the solid was collected by filtration then purified by preparative HPLC to afford 30 mg (13.3%) of l-ethyl-3-[9-methyl-6-(piperidin-l-yl)-8-(4H-l,2,4-triazol- 3-yl)-9H-purin-2-yl]urea.
1H NMR (400 MHz. DMSO-cϋ: δ 1.16 (t, 3H), 1.69 (dd, 6H), 3.26 (q, 2H), 3.97 (s, 3H), 4.20 (br s, 3H), 8.56 (s, IH), 8.94 (s, IH), 9.11 (t, IH).
Example 14 l-Ethyl-3-r9-methyl-6-phenyl-8-(4H-1.2.4-triazol-3-vn-9H-purin-2-yllurea
Hydrazine hydrate (93.45 mg, 1.869 mmol) was added to a stirred solution of l-(8-cyano-9- methyl-6-phenyl-9H-purin-2-yl)-3-ethylurea (Intermediate 21, 300 mg, 0.934 mmol) and formic acid (10 mL) at room temperature. The resulting mixture was refluxed overnight, then cooled to room temperature, and concentrated under reduced pressure. Water was added to the residue and a solid was collected by filtration, then purified by preparative HPLC to afford 40 mg (11.7%) of l-ethyl-3-[9-methyl-6-phenyl-8-(4H-l,2,4-triazol-3-yl)-9H-purin-2-yl]urea. 1H NMR (400 MHz, DMSO-dfi): δ 1.23 (t, 3H), 3.31 (q, 3H), 4.11 (s, 3H), 7.63 (d, 3H), 8.78 (d, 2H), 9.14 (s, IH), 9.72 (s, IH).
Examples 15-17
The following Examples were prepared by the procedure described in Example 14 from the starting materials (SM) indicated.
Example 18
Ethyl 2-(2-r(ethylcarbamoyl)aminol-9-methyl-6-(3-methylphenyl)-9H-purin-8-vU-l,3- thiazole-4-carboxylate
To a stirred solution of 2-[(ethylcarbamoyl)amino]-9-methyl-6-(3-methylphenyl)-9H-purine-8- carbothioamide (Intermediate 25, 0.57 g, 1.54447 mmol) in ethanol (20 mL), ethyl 3-bromo-2- oxopropanoate (1.16 mL, 9.324 mmol) was added, and the mixture was heated to 100 0C for 45 h. After the completion of the reaction, the reaction mixture was concentrated to dryness.
Diethylether (10 mL) was added, and the residue was triturated. The solid obtained was filtered and dried under vacuum to afford 610 mg of crude product (60% in HPLC). The crude product was further purified by preparative HPLC to give 255 mg (35.5%) of product ethyl 2-{2- [(ethylcarbamoyl)amino]-9-methyl-6-(3-methylphenyl)-9H-purin-8-yl}-l,3-thiazole-4- carboxylate as yellow solid.
1H NMR (400 MHz. DMSO-dfi): δ 1.24 (t, 3H), 1.36 (t, 3H), 2.45 (s, 3H), 3.33 (q, 2H), 4.19 (s, 3H), 4.39 (q, 2H), 7.52 (m, 2H), 8.47 (s, IH), 8.57 (d, IH), 8.78 (s, IH), 9.10 (t, IH), 9.83 (s, IH).
Example 19
2-{2-r(Ethylcarbamoyl)aminol-9-methyl-6-(3-methylphenyl)-9H-purin-8-vU-N-methyl-l,3- thiazole-4-carboxamide
In a sealed tube (20 mL), 2-[2-(3-ethyl-ureido)-9-methyl-6-m-tolyl-9H-purin-8-yl]-thiazole-4- carboxylic acid ethyl ester (Example 18, 106 mg, 0.2279 mmol) was taken and methyl amine (15 mL) was added. The reaction mixture was heated to 105 0C for 24 h, then cooled to room temperature, and filtered. The solid obtained was washed with ethylacetate (5 mL) and methanol (5 mL) respectively, then dried to afford 26 mg (24%) of 2-[2-(3-ethyl-ureido)-9- methyl-6-m-tolyl-9H-purin-8-yl]-thiazole-4-carboxylic acid methyl amide as yellow solid. 1H NMR (400 MHz. DMSO-dή): δ 1.25 (t, 3H), 2.50 (s, 3H), 2.87 (d, 3H), 3.30 (q, 2H), 4.25 (s, 3H), 7.54 (m, 2H), 8.58 (m, 3H), 9.11 (br s, IH), 9.77 (br s, IH).
Example 20
2-r2-(3-Ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yll-thiazole-4-carboxylic acid ethyl ester
To a stirred solution of 2-(3-ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purine-8- carbothioic acid amide (Intermediate 26, 0.1 g, 0.268 mmol) in ethanol (5 mL), ethyl 3- bromo-2-oxopropanoate (0.05 mL, 0.402 mmol) was added, and the mixture was heated to 100 0C for 18 h. After completion of the reaction, the reaction mixture was concentrated to dryness. The residue was triturated with diethylether to give a solid, which was filtered and dried under vacuum to afford 0.098 g (61.9%) of 2-[2-(3-ethyl-ureido)-6-(2-fiuoro-phenyl)-9- methyl-9H-purin-8-yl]-thiazole-4-carboxylic acid ethyl ester as solid. 1H NMR (400 MHz. DMSOdn): δ 1.162 (t, 3H), δ 1.35 (t, 3H), δ 3.286 (q, 2H), δ 4.195 (s, 3H), δ 4.38 (q, 2H), δ 7.49 (m, 2H), δ 7.68 (m, IH), δ 8.27 (t, IH), δ 8.77 (s, IH), δ 9.21 (t, IH), δ 9.21 (t, IH), δ 9.85 (s, IH).
Example 21
2-r2-(3-Ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yll-thiazole-4-carboxylic acid
To a stirred solution of 2-[2-(3-ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yl]- thiazole-4-carboxylic acid ethyl ester (Example 20, 0.098 g, 0.208 mmol) in methanol (5 mL) was added 2N sodium hydroxide solution (2 mL). The resulting mixture was stirred at room temperature for 2 h, then concentrated to dryness. The residue was dissolved in water and acidified to pH = 2 with 2N hydrochloric acid solution to get solid, which was filtered and washed with acetonitrile, methanol and diethylether to afford 0.025 g, (28.4%) of 2-[2- (3-ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yl]-thiazole-4-carboxylic acid as solid.
1H NMR (400 MHz. DMSO-dή): δ 1.14 (t, 3H), δ 3.27 (q, 2H), δ 4.195 (s, 3H), δ 7.49 (m, 2H), δ 7.65 (m, IH), δ 8.27 (t, IH), δ 8.70 (s, IH), δ 9.225 (t, IH), δ 9.84 (s, IH), δ 13.4 (bs, IH).
Example 22
2-r2-(3-Ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yll-thiazole-4-carboxylic acid methyl amide
To a stirred solution of 2-[2-(3-ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yl]- thiazole-4-carboxylic acid (Example 21, 0.2 g, 0.454 mM) in dry dimethyl formamide (5 mL), N-methyl morpholine (0.15 mL, 1.36 mM) was added, and the reaction mixture was cooled to 0 0C. HOBt (0.14 g, 0.909 mM) was added, and the mixture was stirred for 10 min. EDCHCl (0.173 g, 0.909 mM) was then added, and the mixture was stirred for 20 min, followed by methyl amine (2M solution in THF) (0.231 mL, 0.454 mM). The reaction mixture was stirred for 18 h, then diluted with water (20 mL) and ethyl acetate (50 mL) and the layers were separated. The organic layer was washed with 2N hydrochloric acid (1 x 25 mL), sodium bicarbonate solution (1 x 25 mL) and brine (1 x 25 mL), respectively. The organic layer was dried and concentrated to give a crude product which was triturated with acetonitrile (5 mL) to give a solid. The solid was collected by filtration, then dried under vacuum to afford 2-[2-(3-ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purin-8-yl]-thiazole- 4-carboxylic acid methyl amide as solid. 1H NMR (400 MHz. DMSOdn): δ 1.16 (t, 3H), δ 2.87 (d,3H), δ 3.27 (q, 2H), δ 4.24 (s, 3H), δ 7.5 (m, 2H), δ 7.67 (m, IH), δ 8.27 (t, IH), δ 8.49 (s, IH), δ 9.22 (t, IH), δ 9.80 (t, IH).
Example 23
2-r2-(3-Ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yll-thiazole-4-carboxylic acid ethyl ester
To a stirred solution of 2-(3-ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purine-8-carbothioic acid amide (Intermediate 28, 1.079 g, 3.85 mmol) in ethanol (20 mL) was added 3-bromo-2- oxopropanoate (0.554 mL, 4.42 mmol). The reaction mixture was heated to 100 0C for 18 h, then concentrated to dryness. Diethyl ether was added to the residue and it was triturated to
give a solid which was collected by filtration and dried under vacuum to afford 1.3 g, (96.4%) of 2-[2-(3-ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yl]-thiazole-4-carboxylic acid ethyl ester as solid.
1H NMR (400 MHz. DMSO-dή): δ 1.16 (t, 3H), δ 1.34 (t, 3H), δ 1.64-1.69 (m, 6H), δ 3.26 (q, 2H, δ 4.075 (s, 3H), δ 4.364 (q, 2H), δ 4.20 (bs, 2H), δ 4.32 (bs, 2H), δ 8.65 (s, IH), δ 8.88 (s, IH), δ 9.25 (s, IH).
Example 24 2-r2-(3-Ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yll-thiazole-4-carboxylic acid
To a stirred solution of 2-[2-(3-ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yl]- thiazole-4-carboxylic acid ethyl ester (Example 23, 0.6 g, 1.31 mmol) in methanol (10 mL) was added 2 N sodium hydroxide solution (7 mL), and the mixture was stirred at room temperature for 5 h. After completion of the reaction, the reaction mixture was concentrated to dryness. The residue was dissolved in water and the solution was acidified with 2N hydrochloric acid causing a solid to precipitate out. The solid was collected by filtration, then co-distilled with toluene (2 x 20 mL) to afford 0.498 g, (88.9%) of 2-[2-(3-ethyl-ureido)-9- methyl-6-piperidin-l-yl-9H-purin-8-yl]-thiazole-4-carboxylic acid as solid. 1H NMR (400 MHz. DMSO-dή): δ 1.16 (t, 3H), δ 1.65-1.694 (m, 6H), δ 3.269 (q, 2H), δ 4.077 (s, 3H), δ 4.25 (bs, 4H), δ 8.568 (s, IH), δ 8.94 (s, IH), δ 9.28 (s, IH).
Example 25
2-r2-(3-Ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yll-thiazole-4-carboxylic acid
In a sealed tube 2-[2-(3-ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yl]-thiazole-4- carboxylic acid ethyl ester (Example 23, 0.3 g, 0.652 mmol) was taken and 30% aqueous ammonia (15 mL) was added. The mixture was heated to 100 0C for 20 h, then the solid that formed was collected by filtration. The solid was washed with acetonitrile and diethyl ether respectively, then dried under vacuum to afford 0.05 g (17.9%) 2-[2-(3-ethyl-ureido)-9- methyl-6-piperidin-l-yl-9H-purin-8-yl]-thiazole-4-carboxylic acid amide solid. 1H NMR (400 MHz. DMSO-dfi): δ 1.15 (t, 3H), 1.62-1.67 (m, 6H), 3.26 (q, 2H), 4.09 (s, 3H), 4.1 (bs, 4H), 7.72 (bs, IH), 7.89 (bs, IH), 8.34 (s, IH), 9.04 (bs, 2H)
Example 26
2-r2-(3-Ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yll-thiazole-4-carboxylic acid methyl amide
To a stirred solution of 2-[2-(3-ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purin-8-yl]- thiazole-4-carboxylic acid (Example 24, 0.2 g, 0.464 mmol) in dry dimethyl formamide (5 mL) was added N-methyl morpholine (0.153 mL, 1.392 mmol). The mixture was cooled to 0 0C and HOBt (0.142 g, 0.928 mmol) was added, followed by methyl amine (2 M solution in THF) (0.225 mL, 0.464 mmol) and then EDCHCl (0.177 g, 0.928 mmol). The mixture was stirred overnight at room temperature, then diluted with ethyl acetate (100 mL) and water (20 mL) then extracted. The organic layer was washed with 2N hydrochloric acid (2 x 25 mL) and bicarbonate wash (50 mL) respectively. The organic layer was dried over anhydrous sodium sulfate then concentrated to a residue which was triturated with acetonitrile. The solid was collected by filtration to afford 0.115 g, (56.31%) of 2-[2-(3-ethyl-ureido)-9-methyl-6- piperidin-l-yl-9H-purin-8-yl]-thiazole-4-carboxylic acid methyl amide as pale yellow solid.
1H NMR (400 MHz. DMSO-cϋ: δ 1.17 (t, 3H), δ 1.62-1.69 (m, 6H), δ 2.85 (d, 3H), δ 3.29 (q, 2H, δ 4.12 (s, 3H), δ 4.24 (bs, 4H), δ 8.34 (s, IH), δ 8.41 (s, IH), δ 9.06 (s, IH).
Example 27 Ethyl 2-(2-(3-ethylureido)-4-(pyridin-4-yl)thienor2,3-dlpyrimidin-6-yl)thiazole-4-carboxylate
2-(3-Ethylureido)-4-(pyridin-4-yl)thieno[2,3-d]pyrimidine-6-carboxamide (Intermediate 41 , 140 mg, 0.41 mmol) was dissolved in THF (5 mL). Lawesson's reagent (165 mg, 0.41 mmol) was added in a single portion and the resulting suspension was heated to reflux. The reaction was about 50% complete after 12 h of heating, so more Lawesson's reagent was added (0.5 mmol). After completion of the reaction, it was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water and then brine, then concentrated to dryness by rotary evaporation. The residue was azeotropically dried with toluene (x2). Then the residue was suspended in toluene (50 mL) and ethyl 3-bromo-2-oxopropanoate (0.057 mL, 0.41 mmol) was added. The reaction mixture was heated to reflux. The reaction was complete (as determined by LC/MS) in 2 h, then cooled to room temperature, wash with water and brine. The organic layer was dry over Na2SOφ filtered and concentrated. The concentrate was purified by silica gel flash column chromatography (gradient 95:5 CH2Cl2/methanol) to give 165 mg of the title compound (90% purity by LC/MS).
LC/MS (ES+)[(M+H)+]: 455 for C20Hi8N6O3S2.
Examples 28-30 The following Examples were prepared by the procedure described in Example 27 from the starting materials (SM) indicated.
Example 31
2-(2-(3-Ethylureido)-4-(pyridin-4-yl)thienor2.3-dlpyrimidin-6-yl)thiazole-4-carboxylic acid:
Ethyl 2-(2-(3-ethylureido)-4-(pyridin-4-yl)thieno[2,3-d]pyrimidin-6-yl)thiazole-4-carboxylate (Example 27, 165 mg, 0.36 mmol) was dissolved in a mixture of THF (3 mL), EtOH (3 mL) and 1 N LiOH (1.5 mL, 1.50 mmol). The solution was stirred at room temperature for 8 h. The pH was adjusted to 1 with 1 M HCl. Water was added to precipitate the product. The solids were filtered and washed with water, then dissolved in minimal DMSO and purified by Gilson HPLC (reverse phase). Isolation gave 7.9 mg of the title compound. LC/MS (ES+)[(M+H)+]: 427 for Ci8Hi4N6O3S2. 1H NMR (300 MHz, d6-DMSO): 1.09 (t, 3H), 3.22 (m, 2H), 7.92 (m, 2H), 8.15 (s, IH), 8.53 (s, IH), 8.78 (t, IH), 8.81 (m, 2H), 10.12 (s, IH).
Examples 32-34
The following Examples were prepared by the procedure described in Example 31 from the starting materials (SM) indicated.
Example 35
2-(4-(Benzo[dlthiazol-2-vπ-2-(3-ethylureido)thienor2,3-dlpyrimidin-6-yl)-N-methylthiazole- 4-carboxamide:
2-(4-(Benzo[d]thiazol-2-yl)-2-(3-ethylureido)thieno[2,3-d]pyrimidin-6-yl)thiazole-4- carboxylic acid (Example 33, 85 mg, 0.18 mmol) and HATU (80 mg, 0.21 mmol) were dissolved in DMF (3 mL) and DIEA (0.092 niL, 0.53 mmol). The solution was stirred for 5 min, then methyl amine (0.097 mL, 0.19 mmol) was added in a single portion. After 1 h the reaction was complete, and the DMF was removed by rotary evaporation. The product was precipitated from solution using IM HCl. The solids were collected, washed with water, dried, and dissolved in minimal DMSO, then purified by Gilson HPLC (reverse phase). Isolation gave 22 mg of the title compound.
LC/MS (ES+)[(M+H)+]: 496 for C2IHi7N7O2S3. 1H NMR (300 MHz, d6-DMSO): 1.27 (t, 3H), 2.84 (d, 3H), 3.37 (m, 2H), 7.66 (m, 2H), 8.32 (m, 2H), 8.43 (s, IH), 8.44 (m, IH), 8.64 (t, IH), 8.82 (s, IH), 10.29 (s, IH).
Examples 36-59
The compounds in Table A were made by methods analogous to the methods described herein above using the appropriate starting materials:
Table A
Preparation of Starting Materials
Intermediate 1
6-Chloropyridine-2,3-diamine
In a 2-neck, 250 mL glass round bottom flask 6-chloro-3-nitropyridin-2-amine (J Med. Chem., 2000, 43, 3053-3066, 5 g, 28.81 mmol) and tin (II) chloride dihydrate (32.5 g, 144.04 mmol) were combined and suspended in EtOAc (90 mL) and
(10 mL).
The reaction slurry was heated to 6O0C for 1 hour. Sodium borohydride (0.544 g, 14.40 mmol) was added in a single portion, and the reaction was heated for an additional 12 hours. The progress of the reaction was monitored by LC/MS. When the reaction was complete, the solvent was removed by rotary evaporation. The solid was dissolved in EtOAc and water. The mixture was neutralized with K2CO3 while cooling the mixture in an ice bath. The tin salts precipitated from solution and were removed by filtering the mixture though a pad of Celite. The aqueous and organic phases were then separated, and the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to 3.2 grams (77% yield) of a light green solid which was used with no further purification. LC/MS (ES+)[(M+H)+]: 144, 146 for C5H6ClN3. 1R NMR (300 MHz, d4-MeOD): 6.47 (d, IH), 6.85 (d, IH).
Intermediate 2
5-Chloro-2-pyridin-3-yl-3H-imidazor4,5-όlpyridine
6-Chloropyridine-2,3-diamine (Intermediate 1, 2.4 g, 16.72 mmol) was dissolved in MeOH (20 mL). Nicotinaldehyde (1.584 mL, 16.72 mmol) was added in a single portion and the reaction was heated to 6O0C. Upon reacting, the solution turned red, and LC/MS showed that the condensation product ([M+H]+: 233, 235 for C11H9CIN4) had formed. The reflux condenser was removed, and the saturated product was aromatized by heating the solution in the presence of air for 4 days. Upon cooling and concentrating a precipitate formed. Ethyl ether (10 mL) was added, then the solids were collected by filtration, washed with ether and dried in vacuo to give 857 mg of the title compound in a 22% yield. LC/MS (ES+)[(M+H)+]: 231, 233 for CnH7ClN4. 1H NMR (300 MHz, d6-DMSO): 7.33 (d, IH), 7.60 (dd, IH), 8.12 (broad singlet, IH), 8.50 (m, IH), 8.72 (dd, IH), 9.36 (dd, IH), 13.66 (d, IH).
Intermediate 3 ferz-Butyl 5-chloro-2-pyridin-3-yl-3/7-imidazor4,5-61pyridine-3-carboxvlate
5-Chloro-2-pyridin-3-yl-3H-imidazo[4,5-ό]pyridine (Intermediate 2, 638 mg, 2.77 mmol) and di-tert-butyl dicarbonate (664 mg, 3.04 mmol) were combined and dissolved in THF (10 mL). Triethylamine (0.463 mL, 3.32 mmol) was added in a single portion along with a few crystals of DMAP. The reaction was then heated to 650C for while monitoring by LC/MS. After one hour, the reaction mixture was concentrated to an oil, the diluted with EtOAc and wash with sat. NH4Cl (x2). The organic layer was dry over Na2SO4, filter and concentrate to a brown solid to give 867 mg of the title compound in a 95% yield which was used with no further purification. LC/MS (ES+)[(M+H)+]: 331, 333 for Ci6Hi5ClN4O2. 1U NMR (300 MHz, CDCl3): 1.5 (s, 9H), 7.43 (d, IH), 7.52 (m, IH), 8.11 (d, IH), 8.30 (d, IH), 8.77 (d, IH), 8.94 (s, IH).
Intermediate 4 6-Chloro-3-nitro-pyridin-2-ylamine
A solution of 2,6-dichloro-3-nitro pyridine (5 g, 26 mmol) in ethanol (50 mL) at 0 0C was purged with ammonia gas for 3 h, then allowed to stir overnight at room temperature. The reaction mixture was diluted with water (100 mL), and the precipitate that formed was filtered and washed with water (50 mL), followed by hexane (50 mL) and dried to obtain 6-chloro-3- nitro-pyridin-2-ylamine in 88% yield (4 g, 23 mmol). MS(ES): 174 (M+l) for C5H4ClN3O2 1R NMR (MeOD, 400 MHz) δ: 6.71 (d, J= 8.6 Hz, IH), 8.39 (d, J= 8.6 Hz, IH).
To ice cold concentrated sulphuric acid was added 6-chloro-3 -nitro-pyridin-2-ylamine (Intermediate 4, 5 g, 28 mmol), and the reaction mixture was stirred for 10 min at 0 0C. A solution OfNaNO2 (4 g, 58 mmol in 30 mL of water) was added slowly over a period of 10 min maintaining the temperature at 00C, then the mixture was stirred for 30 min at the same temperature. The reaction mixture was poured onto ice cold water (150 mL), the precipitate that formed was collected by filtration, washed with cold water (2x50 mL) and dried under vacuum to provide 6-chloro-3-nitropyridin-2(lf/)-one in 80% yield (4 g, 23 mmol) as yellow color solid. MS (ES): 172.9 (M-I) for C5H3ClN2O3.
1H-NMR (DMSO-d6, 400 MHz): δ 7.06 (d, J= 8.3 Hz, IH), 8.40-8.43 (m, IH).
Intermediate 6
3-Aminopyridin-2(l//)-one hydrochloride
To a stirred solution of 6-chloro-3-nitropyridin-2(lH)-one (Intermediate 5, 3.5 g, 20 mmol) in ethyl acetate (50 mL) was added SnCl2.H2O(32 g, 142 mmol) in portions over a period of 15 min at room temperature, then the mixture was re fluxed at 80 0C for 3 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (200 mL) and
neutralized with solid NaHCO3 (50 g). The mixture was filtered and the solids were washed with ethyl acetate (2 x 50 mL). The filtrate was concentrated to remove ethyl acetate under vacuum and the residue was taken in ice cold dioxane (20 mL). 4N HCl in dioxane (10 mL) was added and the mixture was concentrated to give desired product in 95%yield (3.5 g, 19 mmol).
MS (ES): 143.2 (M-I) for C5H5ClN2O
1H-NMR (CDCl3, 300 MHz): δ 4.20 (br s, 2H), 6.20 (d, J= 7.6 Hz, IH), 6.59 (d, J= 7.6 Hz,
IH).
Intermediate 7
N-(6-Chloro-2-hvdroxy-pyridin-3-vD-nicotinamide
To a solution of 3-aminopyridin-2(lH)-one hydrochloride (Intermediate 6, 250 mg, 1.38 mmol) in pyridine (5 mL) was added nicotinoyl chloride (1.6 mmol) slowly over a period of 10 min while maintaining the solution at 0 0C. The reaction mixture was stirred at room temperature overnight, then poured on to ice cold water (20 mL). The precipitate was collected by filtration, washed with water (5 mL) and dried. Recrystallized with ethanol (5 mL) provide the title compound. MS (ES): 250.0 (M+ 1) for C11H8ClN3O2 300 MHz, CDCl3: δ 6.40 (d, IH), 7.40-7.50 (m, IH), 8.20(br s, IH), 8.50 (d, IH), 8.80(br s, IH), 8.90 (br s, IH), 9.20 (br s, IH).
Intermediates 8-10
The following Intermediates were prepared by the procedure described in Intermediate 7 from the starting materials (SM) indicated.
Intermediate 11
5-Chloro-2-pyridin-3-yl-oxazolor5,4-blpyridine
POCl3 was added to N-(6-Chloro-2-hydroxy-pyridin-3-yl)-nicotinamide (Intermediate 7, 28 mmol) slowly at room temperature and then refiuxed at 110 0C for 6 h. The reaction mixture was cooled to room temperature and POCl3 was removed under vacuum. The residue was poured onto ice water (5 mL), and the precipitate that formed was filtered, washed with water and dried to give the corresponding compound.
300 MHz, CDCl3: δ 7.43 (d, IH), 7.50-7.60 (m, IH), 8.05 (d, IH), 8.50 (d, IH), 8.80 (d, IH), 9.49 (s, IH).
Intermediates 12-14
The following Intermediates were prepared by the procedure described in Intermediate 11 from the starting materials (SM) indicated.
Intermediate 15
4-r8-Cvano-2-(3-ethyl-ureido)-9-methyl-9H-purin-6-yll-piperazine-l-carboxylic acid tert- butyl ester
To a stirred solution of l-(6-chloro-8-cyano-9-methyl-9H-purin-2-yl)-3-ethylurea (Intermediate 19, 1.6 g, 5.73 mmol) in ethanol (25 mL), N-Boc piperazine (1.59 mL, 8.6
mmol) was added and the mixture was heated to 100 0C for 18 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and the resulting residue was treated with acetonitrile (5 mL). The solid that formed was collected by filtration and vacuum dried to afford 2.3 g (83.35%) of 4-[8-cyano-2-(3-ethyl-ureido)-9-methyl-9H-purin- 6-yl]-piperazine-l-carboxylic acid tert-butyl ester.
1H NMR (400 MHz. DMSO-dfi): δ 1.15 (t, 3H), 1.43 (s, 9H), 3.05 (t, 2H), 3.227 (t, 2H), 3.48-
3.63 (m, 4H), 3.78 (s, 3H), 4.45 (br s, 2H), 8.83 (t, IH), 9.27 (t, IH).
Intermediate 16
4-r2-(3-Ethyl-ureido)-9-methyl-8-thiocarbamoyl-9H-purin-6-yll-piperazine-l-carboxylic acid tert-butyl ester
To a stirred solution of 4-[8-cyano-2-(3-ethyl-ureido)-9-methyl-9H-purin-6-yl]-piperazine-l- carboxylic acid tert-butyl ester (Intermediate 15, 1.8 g, 4.19 mmol) in ethanol (20 mL), 40% ammonium sulphide (1.07 mL, 6.29 mmol) was added and heated to 100 0C for 18 h. The reaction mixture was cooled to room temperature and the resulting residue was treated with diethylether. The solid that formed was collected by filtration and dried under vacuum to afford 1.83 g (95.3%) of 4-[2-(3-ethyl-ureido)-9-methyl-8-thiocarbamoyl-9H-purin-6-yl]- piperazine-1-carboxylic acid tert-butyl ester. 1H NMR (400 MHz. DMSOdn): δ 1.16 (t, 3H), 1.437 (s, 9H), 3.076 (t, 2H), 3.239 (m, 2H), 3.48-3.64 (m, 4H), 4.004 (s, 3H), 4.45 (br s, 2H), 8.94 (br t, IH), 9.1 (br s, IH), 9.8 (br s, IH), 10.04 (br s, IH).
To a stirred solution of l-(6-Chloro-8-cyano-9-methyl-9H-purin-2-yl)-3-ethyl-urea (Intermediate 19, 1.53 g, 5.48 mmol) in ethanol (25 mL), morpholine (0.73 mL, 8.225 mol) was added and heated to reflux for 15 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and the resulting residue was treated with water (10 mL) and stirred for 30 min. The solid obtained was filtered and dried under vacuum to afford 1.3 g (72%) of l-(8-Cyano-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-3-ethyl-urea as off-white solid.
1H NMR (400 MHz. DMSO-dfi): δ 1.13 (t, 3H), δ 3.24 (q, 2H), δ 3.71 (m, 4H), δ 3.76 (s, 3H), δ 4.36 (bs, 4H), δ 8.84 (t, IH), δ 9.27 (s, IH).
Intermediate 18
2-(3-Ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbothioic acid amide
To a stirred solution of l-(8-cyano-9-methyl-6-morpholin-4-yl-9H-purin-2-yl)-3-ethyl-urea
(Intermediate 17, 1.38 g, 3.93 mmol) in ethanol (20 mL) was added ammonium sulphide (1.0 mL, 5.9 mmol). The reaction mixture was heated to 100 0C for 15 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, then triturated with diethyl ether to give solid compound which was filtered and dried to afford 1.4 g (92%) of 2- (3-ethyl-ureido)-9-methyl-6-morpholin-4-yl-9H-purine-8-carbothioic acid amide as yellow solid.
1H NMR (400 MHz. DMSO-dfi): δ 1.15 (t, 3H), δ 3.25 (q, 2H), δ 3.72 (m, 4H), δ 3.99 (s, 3H), δ 4.21 (bs, 4H), δ 8.95 (s, IH), δ 9.11 (s, IH), δ 9.79 (s, IH), δ 10.05 (s, IH). Mass (APCI. +ve scan): m/z 365 (M+H) for Ci4H20N8O2S.
Intermediate 19 l-fό-Chloro-δ-cvano^-methyl^H-purin^-viyS-ethylurea
A mixture of 2-amino-6-chloro-9-methyl-9H-purine-8-carbonitrile (J Chem Soc, Perkin Trans I, 1977, 1003, 10.0 g, 48.076 mmol), ethyl isocyanate (34.14 g, 480.85 mmol) and dibutyl tin diacetate (1.69 g, 4.814 mM) in a 1:1 mixture of toluene (100 mL) and tetrahydrofuran (100 mL) was heated in an autoclave at 100 0C for 20 h. After the completion of the reaction, the reaction mixture was cooled to room temperature; water (100 mL) was added and the mixture was stirred for 10 min. The layers were separated and organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to afford the crude product. Diethyl ether was added to the crude product and the precipitated solid was filtered and dried to yield 12.0 g (52%) of l-(6-chloro-8-cyano-9-methyl-9H-purin-2-yl)-3- ethylurea. 1H NMR (400 MHz. DMSO-dfi): δ 1.19 (t, 3H), 3.32 (q, 2H), 3.91 (s, 3H), 8.42 (t, IH), 10.30 (s, IH).
Intermediate 20
1 -r8-Cvano-9-methyl-6-(piperidin- 1 -vD-9H-purin-2-yl"|-3-ethvlurea
To a stirred solution of l-(6-chloro-8-cyano-9-methyl-9H-purin-2-yl)-3-ethylurea
(Intermediate 19, 1.2 g, 4.3 mmol) in ethanol (20 mL) was added piperidine (0.638 mL, 6.45 mmol). The reaction mixture was heated to 100 0C for 18 h, then cooled to room temperature and concentrated under reduced pressure. Water (10 mL) was added to the residue and the mixture was stirred for 20 min. The suspension was filtered to afford 1.05 g (75%) of l-[8- cyano-9-methyl-6-(piperidin-l-yl)-9H-purin-2-yl]-3-ethylurea as solid.
1H NMR (400 MHz. DMSO-cϋ: δ 1.14 (t, 3H), δ 1.60-1.67 (m, 6H), δ 3.23 (q, 2H), δ 3.762 (s, 3H), δ 3.88 (brs, 2H), δ 4.42 (brs, 2H), δ 8.91 (s, IH).
Intermediate 21 l-(8-Cvano-9-methyl-6-phenyl-9H-purin-2-ylV3-ethylurea
Argon gas was purged through a mixture of l-(6-chloro-8-cyano-9-methyl-9H-purin-2-yl)-3- ethyl-urea (Intermediate 19, 100 mg, 0.3577 mmol) in toluene (5 mL) for 15 min, then palladium acetate (6.97 mg, 0.0311 mmol), tri-o-tolylphosphine (24 mg, 0.0789 mmol), potassium phosphate (151.6 mg, 0.715 mmol) were added. The reaction mixture was again purged with argon gas for 10 min and phenylboronic acid (86.5 mg, 0.7148 mmol) was added and the mixture was heated to 80 0C for 6 h. The reaction mixture was cooled to room temperature, then passed through a celite bed. The filtrate was concentrated under reduced pressure to obtain a residue which was stirred in diethyl ether for 10-20 min. The solid which formed was collected by filtration and dried to afford 70 mg (60%) of l-(8-cyano-9-methyl-6- phenyl-9H-purin-2-yl)-3-ethylurea.
1H NMR f400 MHz. CDCl1): δ 1.26 (t, 3H), 3.42 (q, 2H), 3.96 (s, 3H), 7.57 (s, IH), 7.60 (dd, 3H), 8.62 (m, 2H), 9.01 (br s, IH).
Intermediates 22-24
The following Intermediates were prepared by the procedure described in Intermediate 21 from the starting materials (SM) indicated.
Intermediate 25
To a stirred solution of l-[8-cyano-9-methyl-6-(3-methylphenyl)-9H-purin-2-yl]-3-ethylurea (Intermediate 22, 0.2 g, 0.597 mmol) in ethanol (10 mL) 40% ammonium sulfide (0.152 mL, 0.8955 mol) was added and the reaction mixture was heated to 100 0C for 38 h. After the completion of the reaction, the reaction mixture was concentrated to dryness. Water (20 mL) was added to the residue added, the mixture was stirred for 10 min. The water was decanted and diethylether (20 mL) was added. A solid formed which was collected by filtration and dried under vacuum to afford 0.17 g (79%) of 2-[(ethylcarbamoyl)amino]-9-methyl-6-(3- methylphenyl)-9H-purine-8-carbothioamide as yellow solid. 1H NMR (400 MHz. DMSOdn): δ 1.23 (t, 3H), 2.45 (s, 3H), 3.32 (q, 2H), 4.00 (s, 3H), 7.48 (m, 2H), 8.47 (s, IH), 8.62 (d, IH), 9.10 (t, IH), 9.82 (br s, IH), 10.18 (br s, IH), 10.54 (br s, IH).
Intermediate 26 2-(3-Ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H-purine-8-carbothioic acid amide
In a sealed tube (20 mL), l-[8-cyano-6-(2-fluoro-phenyl)-9-methyl-9H-purin-2-yl]-3-ethyl- urea (Intermediate 24, 0.1 g, 0.295 mmol) was taken and ethanol (5 mL) was added. To the above reaction mixture 40% ammonium sulphide (0.075 mL, 0.443 mmol) was added. The reaction mixture was heated to 100 0C for 3 h. After the completion of the reaction, the reaction mixture was concentrated to dryness, and water (10 mL) was added to the residue. The mixture was stirred for 10 min and a solid formed which was filtered and dried under vacuum to afford 0.06 g (54.5%) of 2-(3-ethyl-ureido)-6-(2-fluoro-phenyl)-9-methyl-9H- purine-8-carbothioic acid amide.
1H NMR (400 MHz. DMSO-cϋ: δ 1.15 (t, 3H), δ 3.27 (q, 2H), δ 3.97 (s, 3H), δ 7.45 (m, 2H), δ 7.65 (m, IH), δ 8.36 (t, IH), δ 9.226 (t, IH), δ 9.78 (s, IH), δ 10.058 (s, IH), 10.47 (s, IH).
Intermediate 27 l-(8-Cvano-9-methyl-6-piperidin-l-yl-9H-purin-2-yl)-3-ethyl-urea
Piperidine (0.638 mL, 6.45 mmol) was added to a stirred solution of l-(6-chloro-8-cyano-9- methyl-9H-purin-2-yl)-3-ethyl-urea (Intermediate 19, 1.2 g, 4.3 mmol) in ethanol (20 mL).
The reaction mixture was heated to 100 0C for 18 h. After completion of the reaction, the reaction mixture was concentrated to dryness. Water (10 mL) was added to the residue and the suspension that formed was stirred for 20 min. The suspension was filtered and the solid was co-distilled with toluene (2 x 20 mL) to afford 1.05 g (75%) of l-(8-cyano-9-methyl-6- piperidin-l-yl-9H-purin-2-yl)-3 -ethyl-urea as solid.
1H NMR (400 MHz. DMSO-dfi): δ 1.14 (t, 3H), δ 1.60-1.67 (m, 6H), δ 3.23 (q, 2H), δ 3.762 (s, 3H), δ 3.88 (bs, 2H), δ 4.42 (bs, 2H), δ 8.91 (s, IH).
Intermediate 28
2-(3-Ethyl-ureido)-9-methyl-6-piperidin- 1 -yl-9H-purine-8-carbothioic acid amide
To a stirred solution of l-(8-cyano-9-methyl-6-piperidin-l-yl-9H-purin-2-yl)-3-ethyl-urea (Intermediate 27, 1.05 g, 2.08 mmol) in ethanol (20 mL) was added ammonium sulphide (0.533 mL, 3.13 mmol) and the mixture was heated to 100 0C for 18 h. After completion of the reaction, the reaction mixture was concentrated to dryness. The residue was triturated with diethyl ether to give a solid compound which was collected by filtration and dried under
vacuum to afford 1.079 g (86%) of 2-(3-ethyl-ureido)-9-methyl-6-piperidin-l-yl-9H-purine-8- carbothioic acid amide as pale-brown solid.
1H NMR (400 MHz. DMSO-dfi): δ 1.15 (t, 3H), δ 1.60-1.67 (m, 6H), δ 3.23 (q, 2H), δ 3.971 (s, 3H), δ 4.29 (bs, 4H), δ 9.01 (bs, 2H), δ 9.73 (s, IH), δ 10.03 (s, IH).
Intermediate 29
2-Amino-4,6-dichloropyrimidine-5-carbaldehvde
Phosphorus oxychloride (93 mL, 1020.54 mmol) was cooled to 50C using an ice bath. Dry DMF (35 mL) was added slowly with stirring over 30 min to the phosphorus oxychloride. A white precipitate formed during the addition. The reaction mixture was gently warmed (450C) to dissolve the precipitate and produce a clear solution to which was added 2- aminopyrimidine-4,6-diol (24.2 g, 190.40 mmol) in small portions over 1 h, then the mixture was heated at 8O0C. The reaction mixture turned a dark red-brown color. After 12 hours, the reaction mixture was cooled to room temperature and excess POCl^ was removed by rotary evaporation. The oily residue was poured over ice. The mixture became homogeneous and was allowed to stir at room temperature overnight to hydrolyze the Vilsmeier adduct. A yellow solid precipitated from solution and was collected by filtration, washed with water and dried under vacuum. The solid precipitate was recrystallized from hot EtOAc. Isolation gave
27.7 grams of the title compound. Reference: Bell, L., et ah, J. Heterocyclic Cheni., 1983,
20, 41.
LC/MS (ES+)[(M+H)+]: 192, 194 for C5H3ClN3O. 1H NMR (300 MHz, d6-DMSO): 8.51 (s,
2H), 10.06 (s, IH).
Intermediate 30
Ethyl 2-(2-amino-6-chloro-5-formylpyrimidin-4-ylthio)acetate
To a stirred suspension of 2-amino-4,6-dichloropyrimidine-5-carbaldehyde (Intermediate 29, 10.66 g, 55.52 mmol) in ethanol (100 mL), triethylamine (8.51 mL, 61.07 mmol) and ethyl 2- mercaptoacetate (6.12 mL, 55.52 mmol) were added. The reaction mixture was stirred at room temperature for 3 h. The precipitate was collected by filtration and washed with water, then recrystallized from 2-propanol, and dried in vacuo to afford 12.6 grams of the title compound. Reference: Tumkevicius, S. et al., J. Heterocyclic Chem., 2006, 43, 1629-33. LC/MS (ES+)[(M+H)+]: 276, 278 for C9Hi0ClN3O3S. 1R NMR (300 MHz, d6-DMSO): 1.19 (t, 3H), 3.98 (s, 2H), 4.10 (q, 2H), 7.95 (s, IH), 8.25 (s, IH), 10.08 (s, IH).
Intermediate 31
Ethyl 2-amino-4-chlorothieno[2,3-dlpyrimidine-6-carboxylate
A suspension of ethyl 2-(2-amino-6-chloro-5-formylpyrimidin-4-ylthio)acetate (Intermediate
30, 12.6 g, 45.70 mmol) in ethanol (100 mL) and triethylamine (12.74 mL, 91.40 mmol) was refiuxed for 20 h. The solution became homogeneous upon heating, but a solid began to precipitate out of solution after a few hours. The reaction mixture was cooled to room temperature, and the solids were collected by filtration, washed with water, methanol and dried in vacuo to afford 8.21 grams of the title compound. Reference: Tumkevicius, S. et al,
J. Heterocyclic Chem., 2006, 43, 1629-33.
LC/MS (ES+)[(M+H)+]: 258, 260 for C9H8ClN3O2S. 1H NMR (300 MHz, d6-DMSO): 1.31
(t, 3H), 4.31 (s, 2H), 7.70 (br s, 2H), 7.79 (s, IH).
Intermediate 32
In a microwave reaction vessel, ethyl 2-amino-4-chlorothieno[2,3-d]pyrimidine-6-carboxylate (Intermediate 31, 1 g, 3.88 mmol), pyridin-4-ylboronic acid (0.636 g, 4.66 mmol) and sodium carbonate (0.494 g, 4.66 mmol) were combined and suspended in a 4:1 mixture of dioxane and water. Pd(PPh3 )4 (0.224 g, 0.19 mmol) was added in a single portion. The vessel was sealed and heated to 15O0C in the microwave for 30 min. The reaction mixture was diluted with water and methanol, then filtered through a pad of Celite to remove the palladium salts. The filtrate was concentrated by rotary evaporation, and the residue was dissolved in ethyl acetate and washed with water and brine. The organic layer was dried over Na2SOφ filtered and concentrated to a residue which was purified by silica gel flash column chromatography (0-100% EtOAc / hexanes) to afford 30 mg of the title compound. Reference: WO 2005/021552; PCT/GB2004/00364; pg 20.
LC/MS (ES+)[(M+H)+]: 301 for Ci4Hi2N4O2S. 1R NMR (300 MHz, d6-DMSO): 1.31 (t, 3H), 4.31 (s, 2H), 7.70 (br s, 2H), 7.79 (s, IH).
Intermediates 33-35
The following Intermediates were prepared by the procedure described in Intermediate 32 from the starting materials (SM) indicated.
Intermediate 36
Methyl 2-amino-4-(4-(morpholinomethyl)phenyl)thienor2,3-dlpyrimidine-6-carboxylate
Ethyl 2-amino-4-(4-formylphenyl)thieno[2,3-d]pyrimidine-6-carboxylate (Intermediate 35, 550 mg, 1.68 mmol) and morpholine (732 mg, 8.40 mmol) were combined and suspended in
methanol (20 niL). The mixture was heated to reflux for 2.5 h, then cooled to room temperature and sodium borohydride (0.192 mL, 5.04 mmol) was added in a single portion. The mixture was allowed to stirred for 10 min, then it was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over Na2SOφ filtered and concentrated by rotary evaporation. The concentrate was purified by silica gel flash column chromatography (0-100% EtOAc / hexanes) to afford 150 mg of the title compound. Reference: WO 2005/021552; PCT/GB2004/00364; pg 23.
LC/MS (ES+)[(M+H)+]: 385 for Ci9H20N4O3S. 1H NMR (300 MHz, d6-DMSO): 2.40 (m, 4H), 3.57 (m, 6H), 3.85 (s, 3H), 7.37 (br s, 2H), 7.52 (d, 2H), 7.82 (d, 2H), 7.92 (s, IH).
Intermediate 37
Ethyl 2-(3-ethylureido)-4-(pyridin-4-yl)thienor2.3-d1pyrimidine-6-carboxylate
In a microwave reaction vessel, ethyl 2-amino-4-(pyridin-4-yl)thieno[2,3-d]pyrimidine-6- carboxylate (Intermediate 32, 300 mg, 1.00 mmol), ethyl isocyanate (0.785 mL, 9.99 mmol) and dibutyltin diacetate (2.68 μL, 9.99 μmol) were combined and suspended in a 1:1 mixture of THF and toluene. The vessel was sealed and heated to 14O0C in the microwave for 60 min. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over Na2SOφ filter and concentrate, then purified by flash column chromatography (0-100% EtOAc / hexanes) to afford the title compound.
LC/MS (ES+)[(M+H)+]: 372 for Ci7Hi7N5O3S. 1R NMR (300 MHz, d6-DMSO): 1.15 (t, 3H), 1.32 (t, 3H), 3.28 (m, 2H), 4.35 (q, 2H), 7.90 (d, 2H), 8.10 (s, IH), 8.81 (t, IH), 8.86 (d, 2H), 10.27 (s, IH).
Intermediates 38-40
The following Intermediates were prepared by the procedure described in Intermediate 37 from the starting materials (SM) indicated.
2-(3-Ethylureido)-4-(pyridin-4-yl)thienor2,3-d1pyrimidine-6-carboxamide
In a sealed microwave vessel, ethyl 2-(3-ethylureido)-4-(pyridin-4-yl)thieno[2,3- d]pyrimidine-6-carboxylate (Intermediate 37, 222 mg, 0.60 mmol) was suspended in 7N ammonia in methanol (5 mL, 35.00 mmol) and heated to 1000C for 90 min. The vessel was cooled to room temperature and the solids were collected by filtration, washed with cold methanol and dried to afford 197 mg of the title compound (95% pure). LC/MS (ES+)[(M+H)+]: 343 for Ci5Hi4N6O2S. 1R NMR (300 MHz, d6-DMSO): 1.15 (t, 3H), 3.34 (m, 2H), 7.78 (m, IH), 7.90 (m, 2H), 8.27 (m, IH), 8.37 (m, IH), 8.87 (m, 3H), 10.14 (s, IH).
Intermediates 42-44
The following Intermediates were prepared by the procedure described in Intermediate 41 from the starting materials (SM) indicated.
Claims
1. A compound of formula (I'):
R2 is selected from hydrogen or
wherein said
may be optionally substituted by one or more groups independently selected from halo, cyano, hydroxy, nitro and amino;
X1 is selected from =N- or =C(R6)-; X2 and X3 are independently selected from (i) or (ii): (i) -N= or -C(R7)=; (ii) -O-, -S-, -N(R8)- or -C(R9)(R10)-; wherein X2 and X3 are not both selected from (i);
Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R11;
R3' is selected from the group consisting of hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,
C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, Ci_6alkanoyl, Ci_6alkanoyloxy, Λ/-(Ci-6alkyl)amino, Λ/,Λ/-(Ci-6alkyl)2amino, Ci-όalkanoylamino,
Λ7,ΛL(Ci-6alkyl)2carbamoyl, TV-(C i-6alkoxy)carbamoyl, Λ/,Λ/-(Ci.6alkoxy)2Carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2,
Ci-όalkoxycarbonylamino, Λ/-(Ci.6alkyl)sulphamoyl, Λ/,Λ/-(Ci-6alkyl)2sulphamoyl, Ci-όalkylsulphonylamino, carbocyclyl-R12- or heterocyclyl-R13-; wherein R3 may be optionally substituted on carbon by one or more R14 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15;
R6, R7, R9 and R10 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,
C2-6alkenyl,
C2-6alkynyl, Ci_6alkoxy, Ci_6alkanoyl, Ci_6alkanoyloxy, Λ/-(Ci.6alkyl)amino, Λ/,N-(Ci-6alkyl)2amino, Ci.6alkanoylamino, Λ/-(Ci-6alkyl)carbamoyl, Λ/,N-(Ci-6alkyl)2carbamoyl, Λ/-(Ci.6alkoxy)carbamoyl, Λ/,Λ/-(Ci.6alkoxy)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Ci_6alkoxycarbonyl, Ci-όalkoxycarbonylamino, Λ/-(Ci-6alkyl)sulphamoyl, Λ/,Λ/-(Ci-6alkyl)2Sulphamoyl, Ci-όalkylsulphonylamino, carbocyclyl-R12- or heterocyclyl-R13-; wherein R3, R6, R7, R9 and R10 independently of each other may be optionally substituted on carbon by one or more R14; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15; R4 is a substituent on carbon is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl,
Ci_6alkanoyl, Ci_6alkanoyloxy, Λ/-(Ci-6alkyl)amino, Λ/,Λ/-(Ci-6alkyl)2amino, Ci-6alkanoylamino, TV-(C i.6alkyl)carbamoyl, TV>TV-(Ci-6alkyl)2carbamoyl, TV-(C i-6alkoxy)carbamoyl, 7V,7V-(Ci-6alkoxy)2Carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2,
Ci-όalkoxycarbonylamino, 7V-(Ci.6alkyl)sulphamoyl,
7V,7V-(Ci-6alkyl)2Sulphamoyl, Ci-όalkylsulphonylamino, carbocyclyl-R16- or heterocyclyl-R17-; wherein R4 may be optionally substituted on carbon by one or more R18; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R19; n is 0-4; wherein the values of R4 may be the same or different;
R5 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C2-6alkenyl, C2-6alkynyl, Ci_6alkoxy, Ci_6alkanoyl, Ci_6alkanoyloxy, TV-(C i.6alkyl)amino, TV,TV-(Ci-6alkyl)2amino,
R8 is selected from hydrogen,
C3-6cycloalkyl, Ci_6alkanoyl, Ci_6alkylsulphonyl, Ci-όalkoxycarbonyl, carbamoyl, TV-(C i-6alkyl)carbamoyl,
benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R12, R13, R16 and R17are independent selected from a direct bond, -O-, -N(R20)-, -C(O)-, -N(R21)C(O)-, -C(O)N(R22)-, -S(O)8-, -SO2N(R23)- or -N(R24)SO2-; wherein R20, R21, R22, R23 and R24 are independently selected from hydrogen or
and s is 0-2; and R11, R15 and R19 are independently selected from
C3_6cycloalkyl,
benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R14 and R18 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, 7V-methyl-Λ/-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, 7V,7V-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, TV-methyl-iV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, iY,7V-dimethylsulphamoyl, N, N-diethylsulphamoyl or 7V-methyl-7V-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; and R14 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, 7V-methyl-7V-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, 7V,7V-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, TV-methyl-TV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,
7V-methylsulphamoyl, 7V-ethylsulphamoyl, iV,Λ/-dimethylsulphamoyl, 7V,7V-diethylsulphamoyl, τV-methyl-τV-ethylsulphamoyl, and morpholinomethyl.
2. The compound according to Claim 1, wherein: X1 and X2 are both =N-;
X3 is -NR8-; and
R8 is hydrogen or a C^aUcyl.
3. The compound according to Claim 1, wherein: X1 is -C(R7)=;
X2 is =N-; X3 is -NR8-; R7 is hydrogen; and R8 is hydrogen or a C^aUcyl.
4. The compound according to Claim 1, wherein:
X1 is -C(R7)=; X2 is =N-;
X3 is -O-; and R7 is hydrogen.
5. The compound according to Claim 1, wherein: X1 is =N-;
X2 is =C(R7)-; X3 is -S-; and R7 is hydrogen.
6. The compound according to any one of the preceding claims wherein Ring A is carbocyclyl.
7. The compound according to Claim 6, wherein Ring A is phenyl.
8. The compound according to Claim 6, wherein Ring A and (R4)n together are selected from the group consisting of 3-cyanophenyl and 4-cyanophenyl.
9. The compound according to any one of Claims 1 through 5, wherein Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R11.
10. The compound according to Claim 9, wherein Ring A is a pyridyl.
11. The compound according to Claim 9, wherein Ring A is a thiazolyl.
12. The compound according to Claim 9, wherein Ring A is a triazolyl.
13. The compound according to Claim 9, wherein Ring A and (R4)n together are selected from the group consisting of pyrid-3-yl, pyrid-4-yl, 4-(ethoxycarbony)-thiazol-2-yl, 4- carbamoyl-thiazol-2-yl, 4-carboxy-thiazol-2-yl, 4-(7V-methyl-carbamoyl)-thiazol-2-yl, and l,2,4-triazol-3-yl.
14. The compound according to any one of the preceding claims, wherein R3' is a hydrogen.
15. The compound according to any one of Claims 1 through 13, wherein R3 is a heterocyclyl, wherein said heterocyclyl may be optionally substituted on carbon by one or more R14 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R15.
16. The compound according to Claim 15, wherein R3 is selected from the group consisting of piperazin- 1 -yl, morpholin-4-yl, piperidine- 1 -yl, pyrid-4-yl, and benzothiazol-2- yi.
17. The compound according to any one of Claims 1 through 13, wherein R3 is a phenyl which may be optionally substituted on one or more carbon with one or more independently selected R14'.
18. The compound according to Claim 17, wherein R3' is selected from the group consisting of phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-fiuoro-phenyl, and A- (moropholinomethyl)-phenyl.
19. The compound according to any one of the preceding claims, wherein R1 is Ci_6alkyl.
20. The compound according to Claim 19, wherein R1 is ethyl.
21. The compound according to any one of the preceding claims, wherein R2 is hydrogen.
22. A pharmaceutical composition comprising a compound of any one of Claims 1 through
21. or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
23. A method of inhibiting bacterial DNA gyrase and/or bacterial topoisomerase IV in a warm-blooded animal in need of such treatment, comprising administering to the animal an
effective amount of a compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof.
24. A method of producing an antibacterial effect in a warm-blooded animal in need of such treatment, comprising administering to the animal an effective amount of a compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof.
25. A method of treating a bacterial infection in a warm-blooded animal in need thereof, comprising administering to the animal an effective amount of a compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof.
26. The method of Claim 25, wherein the bacterial infection is selected from the group consisting of community-acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections and infections caused by drug resistant bacteria such as Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococci.
27. The method of any one of Claims 23 through 26, wherein the warm-blooded animal is a human.
28. The use of a compound of any one of Claims 1 through 21 , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the production of an antibacterial effect in a warm-blooded animal.
29. The use of a compound of any one of Claims 1 through 21 , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomerase IV in a warm-blooded animal.
30. The use of a compound of any one of Claims 1 through 21 , or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use the treatment of a bacterial infection in a warm-blooded animal.
31. The use of Claim 30, wherein the bacterial infection is selected from the group consisting of community-acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections, Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococci.
32. The use of any one of Claims 28 through 31 , wherein the warm-blooded animal is a human.
33. A compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof, for use in production of an anti-bacterial effect in a warm-blooded animal.
34. A compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof, for use in inhibition of bacterial DNA gyrase and/or topoisomerase IV in a warmblooded animal.
35. A compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof, for use in the treatment of a bacterial infection in a warm-blooded animal.
36. A compound of any one of Claims 1 through 21, or a pharmaceutically acceptable salt thereof, for use in the treatment of community-acquired pneumoniae, hospital-acquired pneumoniae, skin and skin structure infections, acute exacerbation of chronic bronchitis, acute sinusitis, acute otitis media, catheter-related sepsis, febrile neutropenia, osteomyelitis, endocarditis, urinary tract infections, Penicillin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis or Vancomycin-Resistant Enterococci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95794207P | 2007-08-24 | 2007-08-24 | |
US60/957,942 | 2007-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009027732A1 true WO2009027732A1 (en) | 2009-03-05 |
Family
ID=39951715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/050734 WO2009027732A1 (en) | 2007-08-24 | 2008-08-22 | 5-6-bicyclic heteroaromatic compounds with antibacterial activity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009027732A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009131237A1 (en) * | 2008-04-21 | 2009-10-29 | 住友化学株式会社 | Harmful arthropod control composition, and fused heterocyclic compound |
WO2011024004A1 (en) | 2009-08-26 | 2011-03-03 | Astrazeneca Ab | Heterocyclic urea derivatives useful for treatment of bacterial infection |
WO2011121555A1 (en) | 2010-03-31 | 2011-10-06 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
WO2012131588A1 (en) | 2011-03-29 | 2012-10-04 | Actelion Pharmaceuticals Ltd | 3-ureidoisoquinolin-8-yl derivatives |
US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
CN103819489A (en) * | 2014-03-18 | 2014-05-28 | 齐鲁天和惠世制药有限公司 | Preparation method of penicillanic acid sulphoxide diphenyl methyl ester |
EP2923734A1 (en) * | 2009-03-13 | 2015-09-30 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Purine analogues and their use as immunosuppressive agents |
WO2016071499A1 (en) | 2014-11-06 | 2016-05-12 | Basf Se | 3-pyridyl heterobicyclic compound for controlling invertebrate pests |
CN107207530A (en) * | 2014-12-02 | 2017-09-26 | 拜耳作物科学股份公司 | It is used as the dicyclic compound of pest control agent |
WO2018174288A1 (en) | 2017-03-24 | 2018-09-27 | 大正製薬株式会社 | 2(1h)-quinolinone derivative |
EP3424919A1 (en) * | 2013-09-13 | 2019-01-09 | FMC Corporation | Heterocycle-substituted bicyclic azole pesticides |
CN112745317A (en) * | 2020-12-29 | 2021-05-04 | 西南大学 | Purine thiazole compound and preparation method and application thereof |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
AU2018353759B2 (en) * | 2017-10-18 | 2022-07-14 | Hk Inno.N Corporation | Heterocyclic compound as a protein kinase inhibitor |
CN117229258A (en) * | 2022-06-07 | 2023-12-15 | 杭州壹瑞医药科技有限公司 | N-tetrazolyl aryl urea derivative and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060879A2 (en) * | 2000-12-15 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Bacterial gyrase inhibitors and uses thereof |
EP1256578A1 (en) * | 2001-05-11 | 2002-11-13 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
-
2008
- 2008-08-22 WO PCT/GB2008/050734 patent/WO2009027732A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060879A2 (en) * | 2000-12-15 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Bacterial gyrase inhibitors and uses thereof |
EP1256578A1 (en) * | 2001-05-11 | 2002-11-13 | Pfizer Products Inc. | Thiazole derivatives and their use as cdk inhibitors |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2274983A4 (en) * | 2008-04-21 | 2013-10-30 | Sumitomo Chemical Co | Harmful arthropod control composition, and fused heterocyclic compound |
EP2274983A1 (en) * | 2008-04-21 | 2011-01-19 | Sumitomo Chemical Company, Limited | Harmful arthropod control composition, and fused heterocyclic compound |
WO2009131237A1 (en) * | 2008-04-21 | 2009-10-29 | 住友化学株式会社 | Harmful arthropod control composition, and fused heterocyclic compound |
US8242133B2 (en) | 2008-04-21 | 2012-08-14 | Sumitomo Chemical Company, Limited | Arthropod pest control compositions comprising substituted oxazolo [5,4-b ] pyridines |
US8609705B2 (en) | 2008-04-21 | 2013-12-17 | Sumitomo Chemical Company, Limited | Fused heterocyclic compounds, and compositions thereof, for use in arthropod pest control |
US8324387B2 (en) | 2008-04-21 | 2012-12-04 | Sumitomo Chemical Company, Limited | Substituted Oxazolo[5,4-b]pyridines |
US8445522B2 (en) | 2008-04-21 | 2013-05-21 | Sumitomo Chemical Company, Limited | Substituted 2-(4-pyridyl)benzoxazoles, and compositions thereof, for use in arthropod pest control |
AU2009238930B2 (en) * | 2008-04-21 | 2013-07-25 | Sumitomo Chemical Company, Limited | Harmful arthropod control composition, and fused heterocyclic compound |
EP2923734A1 (en) * | 2009-03-13 | 2015-09-30 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Purine analogues and their use as immunosuppressive agents |
WO2011024004A1 (en) | 2009-08-26 | 2011-03-03 | Astrazeneca Ab | Heterocyclic urea derivatives useful for treatment of bacterial infection |
WO2011121555A1 (en) | 2010-03-31 | 2011-10-06 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
US8889676B2 (en) | 2011-03-29 | 2014-11-18 | Actelion Pharmaceuticals Ltd. | 3-ureidoisoquinolin-8-yl derivatives |
WO2012131588A1 (en) | 2011-03-29 | 2012-10-04 | Actelion Pharmaceuticals Ltd | 3-ureidoisoquinolin-8-yl derivatives |
US10822351B2 (en) | 2013-09-13 | 2020-11-03 | Fmc Corporation | Heterocycle-substituted bicyclic azole pesticides |
US11578085B2 (en) | 2013-09-13 | 2023-02-14 | Fmc Corporation | Heterocycle-substituted bicyclic azole pesticides |
EP3424919A1 (en) * | 2013-09-13 | 2019-01-09 | FMC Corporation | Heterocycle-substituted bicyclic azole pesticides |
CN103819489B (en) * | 2014-03-18 | 2015-10-28 | 齐鲁天和惠世制药有限公司 | A kind of preparation method of benzhydryl s-oxopenicillanate |
CN103819489A (en) * | 2014-03-18 | 2014-05-28 | 齐鲁天和惠世制药有限公司 | Preparation method of penicillanic acid sulphoxide diphenyl methyl ester |
WO2016071499A1 (en) | 2014-11-06 | 2016-05-12 | Basf Se | 3-pyridyl heterobicyclic compound for controlling invertebrate pests |
CN107207530A (en) * | 2014-12-02 | 2017-09-26 | 拜耳作物科学股份公司 | It is used as the dicyclic compound of pest control agent |
JP2017537913A (en) * | 2014-12-02 | 2017-12-21 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | Bicyclic compounds as pest control agents The present application relates to novel bicyclic compounds, compositions containing these compounds, their use to control pests, and to prepare them And to intermediates. |
KR20190133667A (en) | 2017-03-24 | 2019-12-03 | 다이쇼 세이야꾸 가부시끼가이샤 | 2 (1H) -quinolinone derivative |
WO2018174288A1 (en) | 2017-03-24 | 2018-09-27 | 大正製薬株式会社 | 2(1h)-quinolinone derivative |
AU2018353759B2 (en) * | 2017-10-18 | 2022-07-14 | Hk Inno.N Corporation | Heterocyclic compound as a protein kinase inhibitor |
US11524968B2 (en) | 2017-10-18 | 2022-12-13 | Hk Inno.N Corporation | Heterocyclic compound as a protein kinase inhibitor |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
CN112745317A (en) * | 2020-12-29 | 2021-05-04 | 西南大学 | Purine thiazole compound and preparation method and application thereof |
CN117229258A (en) * | 2022-06-07 | 2023-12-15 | 杭州壹瑞医药科技有限公司 | N-tetrazolyl aryl urea derivative and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009027732A1 (en) | 5-6-bicyclic heteroaromatic compounds with antibacterial activity | |
EP2102199B1 (en) | Antibacterial polycyclic urea compounds | |
WO2009027733A1 (en) | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents | |
WO2009147431A1 (en) | Thiazolo [5, 4-b] pyridine and oxazolo [5, 4-b] pyridine derivatives as antibacterial agents | |
US20080312211A1 (en) | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 | |
CA2745063A1 (en) | 2- (piperidin-1-yl) -4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections | |
EP2158199B1 (en) | Piperidine compounds and uses thereof | |
US20090325902A1 (en) | Heterocyclic urea derivatives and methods of use thereof | |
US8569484B2 (en) | Heterocyclic urea derivatives and methods of use thereof | |
WO2009147433A1 (en) | Heterocyclic urea derivatives for the treatment of bacterial infections | |
WO2008020227A2 (en) | Antibacterial pyrrolecarboxamides | |
WO2006087544A2 (en) | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors | |
US20100317624A1 (en) | Heterocyclic urea derivatives and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08788705 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08788705 Country of ref document: EP Kind code of ref document: A1 |